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ABBREVIATIONS    
 
ACA - acrodermatitis chronica atrophicans 
AI - antibody index 
CSF - cerebrospinal fluid 
EM - erythema migrans 
IF - intrathecal fraction 
IFA - immunofluorescent assay 
Ig - immunoglobulins 
IQR - interquartile range 
LA - Lyme arthritis 
LB - Lyme borreliosis 
LIAISON - an indirect chemiluminescence immunoassay 
LNB - Lyme neuroborreliosis 
LP - lumbar puncture 
LRFP - pulsed-field gel electrophoresis with identification of large restriction fragment 
patterns 
MKP - modified Kelly-Pettenkofer medium 
OspA, C - outer surface protein A, C 
p - p value 
padj - Holm's adjusted p value 
PCR - polymerase chain reaction 
PFP - peripheral facial palsy 
Q - CSF/serum quotient 
VlsE - variable major protein-like sequence expressed 
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ABSTRACT  
 
Background  
Lyme borreliosis is a zoonosis caused by bacteria from Borrelia burgdorferi sensu lato 
complex. In Europe, it is transmitted to humans by infected Ixodes ricinus ticks. During 
dissemination, when borreliae reach the nervous system, manifestations of Lyme 
neuroborreliosis develop. In adult European patients, Lyme neuroborreliosis is mainly 
caused by B. garinii, followed by B. afzelii, and B. burgdorferi. In adult patients, it has been 
corroborated that the clinical presentation of Lyme neuroborreliosis depends on 
B. burgdorferi sensu lato species. However, data on the etiology of Lyme neuroborreliosis in 
children in Europe is limited, with only scarce data about the influence of B. burgdorferi 
sensu lato species isolated from CSF on clinical presentation of Lyme neuroborreliosis in 
children. 
 
Hypothesis 
In the present study, we wanted to confirm two hypotheses. First, that B. garinii is the main 
cause of Lyme neuroborreliosis in children in Slovenia, as in adult patients, and second, that 
the clinical presentation of Lyme neuroborreliosis in children depends on the B. burgdorferi 
sensu lato species that caused it.  
 
Methods 
The study was mono-centric. During its 17-year period, it included children younger than 15 
years with clinical presentation suggestive of Lyme neuroborreliosis or confirmed Lyme 
borreliosis, who had B. burgdorferi sensu lato isolated from CSF, and who had the species of 
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B. burgdorferi sensu lato identified by pulsed-field gel electrophoresis. Demographic and 
medical data were compared for children infected with various B. burgdorferi sensu lato 
species. Machine learning analysis was performed to search through chosen variables for the 
variable with the highest relative importance score in order to classify children with Lyme 
neuroborreliosis caused by various B. burgdorferi sensu lato species.  
 
Results 
153 children had Borrelia burgdorferi sensu lato isolated from CSF. In 71/113 (62.8%) 
B. garinii, and in 42/113 (37.2%) B. afzelii were identified. Most cases of Lyme 
neuroborreliosis in children occurred between May and August compared to the period from 
September to April (69.0% vs. 31.0%, p=0.012).  
 
Patients infected with B. garinii did not report symptoms suggestive of central nervous 
system involvement or any other symptoms more often than patients infected with B. afzelii. 
In children infected with B. garinii, erythema migrans was seen as the first sign/symptom 
less often (21.1% vs. 45.2%, padj=0.021) compared with children infected with B. afzelii and 
multiple erythema migrans were observed less often on clinical examination (18.3% vs. 
45.2%, padj=0.036). However, children infected with B. garinii presented symptoms of 
meningitis as the first sign/symptom (57.7% vs. 28.6%, padj=0.012), had positive meningeal 
signs on clinical examination (69.0% vs. 38.1%, padj=0.019), had CSF lymphocytic 
predominance (92.9% vs. 65.0%, padj=0.008 ), and had elevated albumin CSF/serum quotient 
(80.6% vs. 50.0%, padj=0.038) more often than children infected with B. afzelii.  
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There were no statistically significant differences in laboratory blood findings, in the 
presence of specific borrelial antibodies in serum and CSF, and in intrathecal specific 
borrelial antibody production between groups of patients infected with B. garinii and 
B. afzelii.  
 
The variable with the highest relative importance score for classification between groups of 
children with Lyme neuroborreliosis caused by B. garinii and B. afzelii is CSF lymphocyte 
concentration, followed by CSF albumin level, and CSF white blood cell count. 
 
Conclusions 
In Slovenia, Lyme neuroborreliosis in children is more often caused by B. garinii, followed by 
B. afzelii. This confirms our first hypothesis. Signs and symptoms of Lyme neuroborreliosis in 
children caused by B. garinii are not more often suggestive of CNS involvement, but CNS 
inflammation is more pronounced in children infected with B. garinii, compared with 
children infected with B. afzelii. Thus, the whole clinical presentation of Lyme 
neuroborreliosis in children depends on B. burgdorferi sensu lato species. This confirms our 
second hypothesis. 
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IZVLEČEK 
 
Uvod 
Lymska borelioza je zoonoza, ki jo povzročajo bakterije iz skupine Borrelia burgdorferi sensu 
lato. V Evropi se človek okuži z vbodom okuženega ščitastega klopa Ixodes ricinus. Če borelije 
v procesu razsoja po telesu vstopijo v živčni sistem, se razvije lymska nevroborelioza. Lymsko 
nevroboreliozo pri odraslih bolnikih v Evropi povzročajo predvsem B. garinii, nato še B. afzelii 
in B. burgdorferi. Dokazali so, da je klinična slika lymske nevroborelioze pri odraslih bolnikih 
odvisna od vrste B. burgdorferi sensu lato, ki jo povzroča. Za populacijo otrok pa so podatki  
o etiologiji lymske nevroborelioze v Evropi skopi in objavljeno je le malo podatkov o vplivu 
vrste B. burgdorferi sensu lato na klinično sliko lymske nevroborelioze pri otrocih.  
 
Hipoteza 
S pričujočo raziskavo smo želeli preveriti dve hipotezi. Prva hipoteza je: “V Sloveniji je pri 
otrocih, enako kot pri odraslih bolnikih, B. garinii najpogostejši povzročitelj lymske 
nevroborelioze.” Druga hipoteza je: “Vrsta B. burgdorferi sensu lato vpliva na klinično sliko 
lymske nevroborelioze pri otrocih.”   
 
Metode 
Raziskava je potekala v enem centru. Trajala je 17 let. V raziskavo smo vključili otroke mlajše 
od 15 let, ki so imeli prisotne klinične znake sumljive za lymsko nevroboreliozo ali potrjeno 
lymsko boreliozo, pri katerih smo osamili B. burgdorferi sensu lato iz likvorja in pri katerih 
smo s pomočjo elektroforeze v utripajočem električnem polju določili vrsto B. burgdorferi 
sensu lato. Bolnike smo razdelili v skupine glede na vrsto osamljene B. burgdorferi sensu 
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lato. Med posameznimi skupinami smo nato primerjali demografske in klinične podatke. 
Izvedli smo tudi analizo strojnega učenja in med izbranimi spremenljivkami poiskali tisto z 
najvišjo oceno relativne pomembnosti za razvrstitev otrok z lymsko nevroboreliozo glede na 
vrsto B. burgdorferi sensu lato.    
 
Rezultati 
V času raziskave smo B. burgdorferi sensu lato iz likvorja osamili pri 153 otrocih. Pri 71/113 
(62.8%) otrocih smo dokazali B. garinii in pri 42/113 (37.2%) otrocih B. afzelii. Več otrok je z 
lymsko nevroboreliozo zbolelo v času od maja do avgusta kot v času od septembra do aprila 
(69.0% vs. 31.0%, p=0.012). 
 
Otroci okuženi z B. garinii niso imeli pogosteje simptomov značilnih za okužbo osrednjega 
živčevja ali katerih koli drugih simptomov kot otroci okuženi z B. afzelii. Pri otrocih okuženih z 
B. garinii so, v primerjavi z otroki okuženimi z B. afzelii, kot prvi znak/simptom bolezni 
erythema migrans opazili redkeje (21.1% vs. 45.2%, padj=0.021) in tudi ob kliničnem pregledu 
smo pri njih multiple erythema migrans našli redkeje (18.3% vs. 45.2%, padj=0.036). Pri 
otrocih okuženih z B. garinii pa so, v primerjavi z otroki okuženimi z B. afzelii, kot prvi 
znak/simptom bolezni simptome značilne za meningitis opazili pogosteje (57.7% vs. 28.6%, 
padj=0.012) in tudi ob kliničnem pregledu so pri njih meningitisni znaki bili prisotni pogosteje 
(69.0% vs. 38.1%, padj=0.019). Otroci okuženi z B. garinii so v likvorju imeli pogosteje prisotno 
limfocitno predominanco (92.9% vs. 65.0%, padj=0.008) in pogosteje zvišan albuminski 
količnik likvor/serum (80.6% vs. 50.0%, padj=0.038), kot otroci okuženi z B. afzelii.  
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Med skupinama bolnikov okuženih z B. garinii ali B. afzelii ni bilo statistično značilnih razlik v 
rezultatih krvnih preiskav, pogostnostjo prisotnosti specifičnih borelijskih protiteles v serumu 
ali likvorju, in tudi ne v pogostnosti intratekalne sinteze specifičnih borelijskih protiteles.  
 
Koncentracija limfocitov v likvorju je spremenljivka z najvišjo oceno relativne pomembnosti 
za razvrstitev otrok z lymsko nevroboreliozo, ki jo povzročata B. garinii ali B. afzelii. Sledita ji 
koncentracija albumina v likvorju in vrednost levkocitov v likvorju.  
 
Zaključki 
Lymsko nevroboreliozo pri otrocih v Sloveniji najpogosteje povzroča B. garinii, nato B. afzelii. 
Tako smo potrdili prvo hipotezo. Klinični znaki in simptomi lymske nevroborelioze pri 
otrocih, ki so okuženi z B. garinii, niso bolj značilni za okužbo osrednjega živčevja, kot pri 
otrocih okuženih z B. afzelii. Vnetje osrednjega živčevja pa je bolj izraženo pri otrocih, ki so 
okuženi z B. garinii, kot pri otrocih okuženih z B. afzelii. Tako vse najdbe skupaj kažejo na to, 
da je klinična slika lymske nevroborelioze pri otrocih odvisna od vrste B. burgdorferi sensu 
lato, ki jo povzroča. Tako smo potrdili drugo hipotezo. 
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1. INTRODUCTION 
 
1.1. LYME BORRELIOSIS 
Lyme borreliosis (LB) is a zoonosis caused by bacteria from Borrelia burgdorferi sensu lato 
complex. It is transmitted mainly from small mammals to humans through the bite of an 
infected tick. It occurs in Europe, North America, and in parts of Asia (1, 2). LB can affect 
many organs, but erythema migrans (EM) is the most frequent clinical sign observed (1–4). 
The disease got the first part of its name from the Lyme region in Connecticut, US, where, in 
1976, groups of children and adults with oligoarthritis were first described (5), and the 
second part from the bacteria that causes it (6, 7).   
 
1.1.1. Epidemiology  
In Europe, there are approximately 85,000 cases of LB reported annually. The highest 
reported incidence rates are in the Baltic States, Sweden, Austria, the Czech Republic, 
Germany, Slovenia, and other parts of central Europe (8). In Slovenia, LB is endemic (4). The 
reported incidence rate in the period 2008 - 2017 was 207 - 337 cases/100,000 population 
(3, 9–11), and in 2017, 4,534 cases were reported (3). In the US, there were 42,743 cases of 
confirmed and probable LB reported in 2017 (12). Fourteen states in the Northeast, mid-
Atlantic, and upper Midwest of the US have reported high incidence rates. The average 
annual reported incidence rates for these states in the period from 2008-2015 ranged from 
10.8 to 69.1/100,000 population. 95.2% of all cases were reported from this region (13). 
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1.1.2. Borrelia burgdorferi sensu lato 
There are 20 different known genospecies of B. burgdorferi sensu lato complex (2). In 
Europe, LB is caused by B. afzelii, B. garinii, B. burgdorferi sensu stricto (B. burgdorferi) (1, 2, 
14–26), B. bavariensis, and very rarely by B. spielmanii, B. bissettii, B. lusitaniae, and 
B. valaisiana (1, 2). In North America, LB is caused nearly exclusively by B. burgdorferi (1, 2), 
and in Asia mainly by B. garinii (1).  
 
Bacteria from the B. burgdorferi sensu lato complex are spirochetes. They have a 
cytoplasmic membrane covered with a peptidoglycan layer, and an outer membrane. There 
is periplasmatic space between the two membranes. At each pole of the cytoplasmic 
membrane, there are flagella attached, and they wind around the bacteria in the 
periplasmatic space. The outer membrane of B. burgdorferi is a lipid bilayer that, unlike in 
Gram-negative bacteria, lacks lipopolysaccharides, but contains phospholipids, glycolipids, 
and lipoproteins. Among these lipoproteins are outer surface proteins A (OspA), and C 
(OspC), which change according to the environment. B. burgdorferi is 10-30 µm long, and 
300 nm wide (2, 6, 27).  
 
Bacteria from B. burgdorferi sensu lato complex have a small genome consisting of a linear 
chromosome that is conserved among different genospecies, and about 20 linear and 
circular plasmids that vary within, and among different genospecies. This variable part of the 
bacteria’s genome contributes to the clinical variability (2, 27). It is known that B. afzelii 
mainly causes skin manifestations, B. garinii is the most neurotropic, and B. burgdorferi is 
the most arthritogenic (1, 2). 
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B. burgdorferi does not synthesize amino acids, lipids, nucleotides, and, due to this limited 
metabolic activity, it depends on the environment in vectors/hosts (1, 2). Thus, 
B. burgdorferi sensu lato also demands complex culture conditions (1, 28).  
 
1.1.3. Vectors, reservoirs, and hosts 
The main reservoir for borreliae are small mammals (mice, voles), birds, and even reptiles (2, 
29). Both infected and uninfected ticks of different life cycle stages, larvae and nymphs, feed 
on these animals (2, 30). During feeding, the uninfected ticks acquire borreliae from the 
infected reservoir animal (systemic transmission) or from an infected tick that is feeding 
close by at the same time on the same reservoir animal (co-feeding transmission) (30). 
Transovarial transmission does not exist or is rare (1). On the other hand, deer are only the 
hosts for the ticks (2, 29). As such, deer are important for the maintenance of the tick 
population (2). Once in the tick, borreliae can be transmitted to humans during a blood 
meal. In Europe, the vector of B. burgdorferi sensu lato is the Ixodes ricinus tick, in Asia 
Ixodes persulcatus, on the North American East coast Ixodes scapularis and on the West 
coast Ixodes pacificus (1, 2, 31). 
 
1.1.4. Pathogenesis and immunologic response 
While in the tick midgut, the borreliae express lipoprotein OspA. After the tick attaches to a 
mammal and becomes engorged with blood, the expression of OspA is downregulated, and 
the expression of OspC is upregulated. OspC enables the borreliae to invade the tick’s 
salivary glands and, for this reason, OspC is necessary to establish early infection in 
mammals. The tick delivers the borreliae to the skin, where they multiply (1, 2).  
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At the site of the tick bite, EM develops (2, 32–34). There, one can find cellular infiltrate 
consisting of T cells (CD4+, CD8+), neutrophils, dendritic cells, and monocytes/macrophages. 
Proinflammatory cytokines (TNF, IL-2, IL-6, type I-IFN), and chemokines that attract 
neutrophils (CXCL1), macrophages (CCL3, CCL4), and T cells (CXCL9, CXCL10, CXCL11) are 
produced. The complement system augments phagocytosis. In about 24 hours, the 
neutrophils are gone from the site. In a couple of days, interstitial and perivascular infiltrates 
form, consisting of lymphocytes, plasma cells, rarely mast cells, and IL-10 with anti-
inflammatory actions is produced (2) by mononuclear cells when stimulated by borreliae 
(35).  
 
On the other hand, once in the host, the borreliae evade the immune system by several 
means. There are complement blocking substances in tick saliva (Salp15, Salp20, ISAC, IRAC) 
(35), and borreliae themselves express CRASPs (complement regulator-acquiring surface 
proteins) on their surface. These two mechanisms help the borreliae to evade the innate 
immune system (2, 35). Borreliae evade the adaptive immune response by replacing surface 
lipoprotein OspC with lipoprotein VlsE (variable major protein-like sequence expressed). VlsE 
undergoes genetic variation and thus enables the borreliae to escape the bactericidal 
antibodies (1, 2). Borreliae can also release soluble antigens that bind to specific borrelial 
antibodies produced by B cells, thus impairing the opsonization and killing of borreliae (35).  
 
From the skin, borreliae later spread through tissues, blood, and lymphatic vessels. Among 
the many surface lipoproteins, borreliae also have fibronectin-binding proteins BBK32, which 
enable them to attach to the vascular surface, from which they migrate to the tissue (1, 2). 
The same pattern of inflammation repeats at the tissues that are reached (skin, heart, joints, 
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central nervous system (CNS)) (2). Borreliae are motile due to their flagella and locally induce 
production of metalloproteinase-9, which digests the extracellular matrix. Borreliae attach to 
the proteins in the extracellular matrix, thus hiding from the host defense mechanisms in a 
less accessible space (35).  
 
Some studies have described differences in pathogenicity and inflammatory response for 
different B. burgdorferi sensu lato species and subtypes (36–39). For example, Strle K. et al 
have shown that in vitro, by stimulating macrophages, and in vivo, by testing the patients’ 
sera, B. burgdorferi from the US has greater inflammatory potential than B. afzelii and 
B. garinii from Europe (39).  
 
Manifestations of the disease develop mainly due to the host inflammatory responses 
described above (1, 2).  
 
1.1.5. Clinical manifestations of Lyme borreliosis 
If left untreated by antibiotics, three stages of LB can be observed: localized infection, early 
disseminated disease, and late infection (1, 2, 33).  
 
At the site of a tick bite (2, 32–34), EM can develop within days or weeks; that being a sign of 
localized infection (1, 2, 32, 33). EM is the most common clinical manifestation of LB (66-
90%) (1, 2, 32, 33, 40). It can be homogenous or annular (1, 41, 42), and is diagnosed 
clinically (1, 2). In the US, where it is caused by B. burgdorferi, it is usually accompanied by 
systemic symptoms (2, 32, 34, 43). Some differences between EM occurring in different US 
states have been described (44). In Europe, when EM is caused by B. garinii, it can be 
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accompanied by pain, itching, burning sensation (2, 41) and some systemic symptoms (41), 
and it spreads faster than when it is caused by B. afzelii (2, 41, 42) or B. burgdorferi (2). In 
Europe, borrelial lymphocytoma can also be observed as a sign of localized infection and is 
most often caused by B. afzelii (2). It is more frequent in children (1, 45). The most frequent 
location of borrelial lymphocytoma is the earlobe (46), and other locations are the helix, 
nipple, and scrotum (1, 2, 32, 46). 
 
Subsequently, within days to weeks, dissemination of borreliae through the blood stream, 
and possibly through tissue planes, can occur, and signs/symptoms of early disseminated 
disease develop (1, 2, 47). One can observe multiple EM, signs/symptoms of early Lyme 
neuroborreliosis (LNB) and, rarely, Lyme carditis (atrioventricular nodal block, 
myopericarditis, rarely mild left ventricular dysfunction, cardiomegaly or pancarditis) (1, 2, 
32, 33, 45, 48–50).  
 
If the infection progresses even further, within months to years, the signs/symptoms of late 
infection develop. These are Lyme arthritis (LA), acrodermatitis chronica atrophicans (ACA), 
and late LNB (2). LA can present as monoarthritis or oligoarthritis (1, 2, 45) and can be the 
presenting symptom of LB (45, 48). This occurs in both the US and Europe. In the US, it 
affects large joints, especially the knee (90%). In Europe, it is not as frequent, and can occur 
earlier in the disease (2). ACA occurs almost exclusively in Europe, mostly due to infection 
with B. afzelii (2, 45, 51), and rarely due to infection with B. garinii or B. burgdorferi (2). It 
usually affects older women. It occurs rarely in children and only case reports have been 
described (2, 45, 51). The lesions are usually present on the extensor surfaces of extremities. 
They are red, bluish and edematous at first, and later become atrophic (1, 2, 51). Late LNB is 
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rare (1), especially in children (33). In Europe, severe chronic encephalomyelitis, and in the 
US, mild encephalopathy and mild axonal neuropathy were described (1, 2).  
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1.2. LYME NEUROBORRELIOSIS 
In the process of dissemination, when borreliae reach the nervous system, manifestations of 
LNB develop (1, 47). 
 
1.2.1. Etiology of Lyme neuroborreliosis  
In adult European patients with LNB, studies have shown the presence of B. garinii, B. afzelii 
and B. burgdorferi in cerebrospinal fluid (CSF) (15, 17, 18, 21). Further, they have shown that 
LNB in these patients is mainly caused by B. garinii, followed by B. afzelii and B. burgdorferi 
(52, 53). In North America, LB is only caused by B. burgdorferi (1).  
 
Data on the etiology of LNB in children in Europe is limited. In Slovenia, B. garinii was 
isolated from CSF in 14% of children with peripheral facial palsy (PFP) (54) and both B. afzelii 
and B. garinii were isolated from CSF in 4% of children with multiple EM (55). In one study in 
Norway, mainly B. garinii was determined by polymerase chain reaction (PCR) in CSF of 
children with early LNB (14). 
 
1.2.2. Clinical manifestations of Lyme neuroborreliosis 
In adults, LNB can manifest as meningoradicultis, meningitis, PFP, encephalitis, myelitis and 
cerebral vasculitis (1, 56).  
 
In children, the main presentations of LNB are meningitis and PFP (1, 45, 48). Other clinical 
manifestations of LNB in children are rare and merely described as case reports. These rare 
clinical manifestations are: isolated palsies of other cranial nerves (trochlear nerve, 
abducens nerve, oculomotor nerve), cranial polyneuritis, optic neuritis, panuveitis, regional 
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meningitis, meningoecephalitis, meningoradiculitis, polyradiculoneuritis, acute transverse 
myelitis, acute disseminated encephalomyelitis, transient ischemic attack, cerebrovascular 
insult, intracranial vasculitis, nystagmus, opsoclonus-myoclonus, ataxia, vertigo, idiopathic 
intracranial hypertension, psychosis, sleep disturbances, and Alice in Wonderland syndrome 
(32, 48, 57–84). 
 
A Slovenian study conducted by Strle et al. in patients older than 15 years with B. garinii and 
B. afzelii isolated from CSF found that B. garinii causes Bannwarth syndrome and that 
B. afzelii causes less specific clinical presentation of LNB (52). In a recent study by Barstad et 
al., children with early LNB caused by B. garinii did not have uniform clinical picture (14).  
 
1.2.3. Diagnosis of Lyme neuroborreliosis 
In Europe, LNB is confirmed when all three of the following criteria are met: neurologic 
symptoms suggestive of LNB without other obvious reasons, CSF pleocytosis, and intrathecal 
specific B. burgdorferi sensu lato antibody production (1, 85, 86). If only two of the three 
criteria are met, LNB is possible. These criteria are not valid for late LNB (85). Presence of 
specific B. burgdorferi sensu lato antibodies in serum, detection of B. burgdorferi sensu lato 
by culture and/or PCR from CSF, intrathecal synthesis of total IgM and/or IgG and/or IgA, and 
recent or concurrent EM are supporting evidence for the diagnosis of LNB (1, 86). However, 
isolation of B. burgdorferi sensu lato from CSF stands for definite diagnosis of LNB (2, 86, 87). 
But, cultivation of borreliae from CSF is not routinely used, due to low sensitivity, slow 
growth of borreliae, and the need for a specialized laboratory (85).  
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2. BACKGROUND and AIM 
 
2.1. Background 
Information on the etiology of LNB in children in Europe is limited (54, 55), with only scarce 
data about the influence of B. burgdorferi sensu lato species isolated from CSF on clinical 
presentation of LNB in children (14). Furthermore, Slovenia is a small Central European 
country with two million inhabitants, where LB is endemic (4). High incidence rate (3, 4) and 
the research-oriented management of patients with LB has enabled us to obtain insight into 
the etiology of LNB in children, and to compare groups of children with LNB caused by 
different B. burgdorferi sensu lato species.  
 
2.2. Aim 
The aims of the present study were: 
(I) to establish the etiology of LNB in children in Slovenia, and  
(II) to compare the demographic, clinical, and laboratory findings in children infected with 
B. afzelii to those infected with B. garinii.  
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3. HYPOTHESIS 
 
1. B. garinii is the main cause of LNB in children in Slovenia, as in adult patients. 
 
2. The clinical presentation of LNB in children depends on the B. burgdorferi sensu lato 
species that caused it.  
 
 
I expect B. garinii to be the main cause of LNB in children in Slovenia.  
I expect the clinical presentation of LNB in children to depend on the B. burgdorferi sensu 
lato species that caused it. 
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4. MATERIAL AND METHODS 
The clinical part of the study was carried out at the Department of Infectious Diseases, 
University Medical Centre Ljubljana, while the microbiologic tests were performed at the 
Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, 
Slovenia.  
 
4.1. Study design 
The data for the present study were obtained prospectively for all of the patients as a part of 
various studies using the same clinical protocol in previous years (54, 55, 88–91). The 
Medical Ethics Committee at the Ministry of Health of the Republic of Slovenia approved the 
protocols for the previous studies (No. 17/04/96, No. 55/04/01, No. 28/02/04, No. 56/04/04, 
No. 47/07/04) and the present study (No. 166/02/13). Informed consent from parents/legal 
guardians was obtained before the enrolment of patients into the studies. 
 
4.2. Patients 
Children younger than 15 years with clinical presentation suggestive of LNB (patients with 
clinical syndrome of serous meningitis, PFP, patients with febrile illness after a tick bite with 
symptoms suggestive of nervous system involvement) or confirmed LB (multiple EM), 
admitted to the Department of Infectious Diseases in the period from 1st January 1996 to 
31st December 2012, qualified for the study.  
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4.3. Clinical and laboratory workup 
Upon admission, demographic features, medical history, and clinical data were obtained 
using a questionnaire. Detailed physical and neurologic examinations were performed. Basic 
hematologic and biochemical tests, as well as a lumbar puncture (LP) were performed. In 
CSF, a white blood cell count of ≥ 5 × 106/l was considered to be pleocytosis. In patients with 
pleocytosis, we searched for lymphocytic predominance. CSF flow rate and intrathecal total 
antibody production were defined by the Reiber and Peter criteria (92). For each patient, the 
concentrations of albumin, immunoglobulins G (IgG), A (IgA), and M (IgM) in blood and in 
CSF were determined, while the albumin (QAlb), IgG (QIgG), IgA (QIgA), and IgM (QIgM) 
CSF/serum quotients were calculated. The fraction of intrathecally produced unspecific IgG 
(IgGIF), A (IgAIF), M (IgMIF) was calculated. A value of >10% was considered positive.  
 
4.4. Determination of borrelial antibodies 
At the initial examination, blood and CSF samples were collected for determination of 
specific borrelial IgM and IgG antibodies. For all of the patients, they were determined by an 
in-house indirect immunofluorescence assay (IFA), as previously described (93). The most 
dominant Slovenian isolate (24), B. afzelii was used as the antigen. First, the borrelia strain 
was cultured in modified Kelly-Pettenkofer (MKP) medium (28). The growing culture was 
centrifuged, washed in phosphate buffered saline with MgCl2, analyzed for the presence of outer 
surface proteins (Osp), and dropped onto slides that were dried at room temperature. Slides 
were stored at -80°C, ready for testing. Second, the patients’ sera and CSF samples were diluted 
in buffer at dilutions from 1:64 to 1:512, and dilutions from 1:2 to 1:16, respectively. Diluted 
samples were added to prepared slides, and complexes were incubated for 30 minutes at 37°C. 
After incubation, the slides were washed in buffer three times, and anti-human IgM and IgG 
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antibodies conjugated with fluorescein-5-isothiocyanate were added. The complexes were once 
more incubated, and washed, as before. Finally, the slides were examined under fluorescence 
microscopy. Serum IFA antibody titers ≥ 1:256 and CSF IFA antibody titers ≥ 1:16 were 
considered positive (89, 90, 93). 
 
Additionally, for patients with stored serum and CSF samples, borrelial IgM and IgG were 
determined by an indirect chemiluminescence immunoassay (LIAISON®, DiaSorin, Salugga, 
Italy). The solid phase of the test included magnetic particles coated with recombinant 
antigens (OspC and VlsE for IgM, and VlsE for IgG antibody detection), with which, during the 
first incubation, borrelial antibodies in serum or CSF samples bind. The unbound material is 
washed away. During the second incubation, mouse monoclonal antibodies conjugated to an 
isoluminol derivate react with solid phase, already bound IgM or IgG antibodies. Again, the 
unbound material is washed away. At the end, the starter reagent is added to produce a 
flash chemiluminescence reaction. Using a photomultiplier, the amount of isoluminol-
antibody conjugate is measured as relative light units (RLU) (93). The results for specific IgM 
and IgG antibodies are given as arbitrary units/ml (AU/ml) and interpreted according to the 
manufacturer’s instructions. A serum LIAISON antibody concentration of >22 AU/ml and 
>15 AU/ml for IgM and IgG, respectively, and a CSF LIAISON antibody concentration of >3.5 
AU/ml and > 5.5 AU/ml for IgM and IgG, respectively, were considered positive. 
 
4.5. Antibody index 
For patients who had positive specific borrelial IgM and/or IgG antibodies in CSF determined 
by IFA and/or LIAISON, the intrathecal synthesis of specific borrelial IgM and/or IgG 
antibodies were determined by calculating the antibody index (AI). For patients with 
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antibodies determined by IFA, AI was calculated using the formula in Figure 1. An AI of > 1.4 
was considered positive (92). For patients with antibodies determined by LIAISON, AI was 
calculated using an Excel formula provided by the manufacturer. That formula also includes 
serum and CSF albumin levels. An AI of > 1.4 was considered positive. 
 
Figure 1: Formula for calculation of AI. 
AI IgM (G) 𝐵. 𝑏𝑢𝑟𝑔𝑑𝑜𝑟𝑓𝑒𝑟𝑖 sensu lato =  
IgM(G) 𝐵. 𝑏𝑢𝑟𝑔𝑑𝑜𝑟𝑓𝑒𝑟i sensu lato (CSF) x IgM(G) (serum)
IgM(G) 𝐵. 𝑏𝑢𝑟𝑔𝑑𝑜𝑟𝑓𝑒𝑟𝑖 sensu lato (serum) x IgM(G) (CSF) 
 
AI - antibody index, Ig – immunoglobulins (M, G), CSF - cerebrospinal fluid 
 
 
4.6. Cultivation of Borrelia burgdorferi sensu lato 
Plasma and CSF samples were inoculated into a MKP medium (24, 94). They were examined 
weekly for the presence of spirochetes by dark-field microscopy for up to 9 or 12 weeks for 
CSF or blood samples, respectively.  
 
4.7. Identification of Borrelia burgdorferi sensu lato 
For species identification, the cultured spirochetes were centrifuged, washed in TN (Tris-
NaCl) buffer, and embedded in low melting point agarose. Plugs were incubated in lysis 
buffer at 37⁰C for 24 h and in digestion buffer at 50⁰C for 72 h. Later, they were washed in 
TE (Tris-EDTA) buffer and stored at +4⁰C, ready to be analyzed. One plug was digested using 
MluI restriction enzyme. Digested borrelial DNA was analyzed by pulsed-field gel 
electrophoresis with identification of large restriction fragment patterns (MluI-LRFP) (15, 25, 
31).  
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Where identification of Borrelia strains was not possible by MluI-LRFP, due to insufficient 
growth in the culture, PCR was used. Two methods were performed. One method was PCR 
of the 5S-23S intergenic region, followed by MseI restriction and fragment identification 
according to typical MseI restriction fragment length patterns (MseI-RFLP) (95). The other 
method was real time PCR of hbb gene followed by Tm (melting temperature) 
determination. Gained Tm enabled us to identify particular Borrelia species (96). 
 
4.6. Inclusion criteria 
Patients who had LP performed, had B. burgdorferi sensu lato isolated from CSF, and had 
species of B. burgdorferi sensu lato identified by MluI-LRFP, were enrolled for the present 
study.  
 
4.7. Statistical analysis 
Patients were divided into groups according to the species of B. burgdorferi sensu lato 
identified by MluI-LRFP. The data were analyzed using IBM SPSS Statistics, version 21. The R 
programming language was utilized to implement machine-learning procedures. 
 
First, numerical data were summarized as medians (interquartile range, IQR), and categorical 
data as frequencies (%). 95% confidence intervals (CIs) for percentages were based on exact 
binomial distributions. Differences in the continuous variables were tested by t-test, Welch 
t-test or Mann-Whitney U test, as appropriate. Differences in the categorical data were 
analyzed using chi-square test or Fisher exact test. The normality assumption and 
assumption of homoscedasticity (e.g., equal variances) were tested using the Shapiro-Wilk 
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test and Bartlett test, respectively. Holm's method was used to adjust p values to control the 
Type I error. A Holm’s adjusted p value (padj) of < 0.05 was considered statistically significant. 
 
Second, statistical learning techniques were performed to classify and assess the 
performance of classification between B. garinii and B. afzelii samples. In the original data 
set of chosen variables for this statistical analysis, variables with a missing rate of > 50% 
were removed. Other missing values for remaining variables were imputed using median 
value for numerical variables and mode value for categorical variables. Numerical variables 
were standardized before further processing. The imbalance between classes (42 B. afzelii 
and 71 B. garinii samples) may seriously impact the performance of machine learning 
methods (97), hence, the SMOTE procedure was used – a technique which combines over-
sampling and under-sampling to balance classes in a data set (98). In our study, five 
machine-learning classifiers were applied and evaluated. Namely, k-nearest neighbors (kNN), 
classification tree (CT), random forest (RF), gradient boosting machine (GBM), and extreme 
gradient boosting (XGBoost) (99).  
 
To assess the performance of the learning classifier, such as sensitivity (proportion of 
B. afzelii samples correctly identified) and specificity (proportion of B. garinii samples 
correctly identified), standard metrics per class were used. Global accuracy (average of total 
samples correctly identified among the total number of samples examined) and area under 
the ROC curve (AUROC) were also reported. The AUROC of the perfect model can reach 1, 
while random guessing is equal to 0.5. 
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In addition to the performance evaluation of machine-learning classifiers, relative 
importance of chosen variables that contribute to statistical learning were examined. The 
machine-learning classifier with the best performance was selected as a baseline, as it 
provides the best indication of which chosen variables are most important in the 
classification process. For each chosen variable, the importance was computed using a 
relative score (0-100).   
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5. RESULTS 
In the study period of 17 years, there were 153 consecutive children younger than 15 years 
with clinical presentations suggestive of LNB, or with confirmed LB (multiple EM), who had 
B. burgdorferi sensu lato isolated from CSF. 
 
5.1. Etiology 
In 40/153 (26.1%) patients, the borreliae did not grow well enough to enable species 
identification by MluI-LRFP. In 15/40 (37.5%) of these patients, PCR was positive for B. afzelii, 
in 10/40 (25.0%) patients, PCR was positive for B. garinii, and in 5/40 (12.5%) of patients, 
PCR was positive for both B. afzelii and B. garinii. In 10/40 (25.0%) the identification of 
B. burgdorferi sensu lato species was impossible, even by PCR. These 40 patients were 
excluded from further analysis. 
 
In the remaining 113/153 (73.9%) patients, the species of B. burgdorferi sensu lato was 
identified by MluI-LRFP. 71/113 (62.8%) isolates were identified as B. garinii (subtypes 
BgMlg2 - 67, BgMlg4 - 4), and 42/113 (37.2%) as B. afzelii (subtype BaMla1 - 42). These 113 
patients were included for further analysis. 
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5.2. Demographic and epidemiologic features 
Demographic and epidemiologic features and some clinical characteristics of children with 
LNB are shown in Table 1. Regarding the gender and age of the patients, as well as the 
duration of the first sign/symptom before admission, the two etiologic groups were 
comparable. There were 18/113 (15.9%) patients that had previous LB in the last 120 days 
prior to the current disease.   
 
Table 1: Demographic features of children with Lyme neuroborreliosis caused by B. garinii 
and B. afzelii. 
 B. garinii B. afzelii p padj 
No. of patients 71 42   
Gender1     
Female 28 (39.4) 18 (42.9) 0.843 > 0.999 
Age  
Median (years) (IQR)  
6.5 (4.9-8.9) 4.8 (3.5-9.5) 0.186 > 0.999 
Female 5.9 (4.6-7.7) 4.3 (3.7-5.5) 0.051 0.663 
Male 6.8 (5.4-10.4) 7.1 (3.3-10.9) 0.902 > 0.999 
Tick bite in the last 90 
days1 
35 (49.3) 13 (30.9) 0.076 0.912 
Site of the bite1   0.930 > 0.999 
Trunk 10 (28.6) 4 (30.8) 0.566 > 0.999 
Head or neck 5 (14.3) 3 (23.1) > 0.999 > 0.999 
Extremities 4 (11.4) 1 (7.7) 0.649 > 0.999 
Unknown 16 (45.7) 5 (38.5) 0.213 > 0.999 
Days from a bite to first 
symptoms  
Median (IQR) (days) 
29 (23.0-60.0) 30 (21-57.0) 0.956 > 0.999 
Duration of 
signs/symptoms before 
admission 
Median (IQR)(days) 
4.0 (2.0-6.0) 4.0 (1.0-10.8) 0.689 > 0.999 
Previous LB1 11 (15.5) 7 (16.7) > 0.999 > 0.999 
Solitary erythema migrans 11  6    
Multiple erythema migrans 0  1    
1Number of patients (%), IQR - interquartile range, LB - Lyme borreliosis, padj - Holm's 
adjusted p value 
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Most cases of LNB occurred between May and August (78/113, 69.0%) compared to the 
period from September to April (35/113, 31.0%, p=0.012) (Figure 2). The difference 
regarding the monthly distribution of patients between the groups of LNB caused by 
B. garinii and B. afzelii was not statistically significant (p=0.278). On average, there was one 
isolation of B. burgdorferi sensu lato from CSF every five to six weeks, and there were 1-12, 
and 0-5 patients yearly with B. garinii and B. afzelii isolated from CSF, respectively. 
 
Figure 2: Number of children with Lyme neuroborreliosis caused by B. garinii (71 patients) 
and B. afzelii (42 patients) registered by month. 
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5.3. Signs and symptoms of Lyme neuroborreliosis 
 
5.3.1. The first signs/symptoms  
The first signs/symptoms of disease noticed by patients/parents in children with LNB are 
shown in Table 2. The two groups differ regarding the first signs/symptoms noticed (padj= 
0.005). Symptoms of meningitis were more common in the B. garinii group, while EM and 
“other” first signs/symptoms were more frequent in the B. afzelii group. In the 
heterogeneous group of “other first signs/symptoms” were one patient with only fever, one 
with bilateral lymphocytoma, one with arthralgia, and one patient with eating disorder. 
 
Table 2: The first sign/symptom of disease noticed by patients/parents in children with Lyme 
neuroborreliosis caused by B. garinii and B. afzelii. 
 
 B. garinii B. afzelii p  
 
padj 
No. of patients 71 42   
The first sign/symptom noticed1    0.001 0.005 
Symptoms of meningitis 41 (57.7) 12 (28.6) 0.003 0.012 
Erythema migrans 15 (21.1) 19 (45.2) 0.007 0.021 
Peripheral facial palsy 15 (21.1) 7 (16.7) 0.563 0.563 
Other 0 (0) 4 (9.5) 0.017 0.034 
1Number of patients (%), padj - Holm's adjusted p value 
 
 
5.3.2. Associated symptoms  
Altogether, at initial examination, 87/113 (76.9%) patients reported associated symptoms in 
the period from disease onset up to admission. 71/113 (62.8%) patients reported headache 
and 39/113 (34.5%) reported fever (Table 3). There were no statistically significant 
differences between patients with LNB caused by B. garinii and those in whom B. afzelii was 
isolated from CSF (Table 3). 
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Table 3: Associated symptoms in the period from disease onset up to admission in children 
with Lyme neuroborreliosis caused by B. garinii and B. afzelii. 
 B. garinii B. afzelii p padj 
No. of patients 71 42   
Symptoms1 61 (85.9) 26 (61.9) 0.003 0.078 
No. of symptoms/patient 
Median (IQR) 
3 (2.0-4.0) 2 (0.0-3.8) 0.032 0.704 
Number of events (%)     
Headache 51 (71.8) 20 (47.6) 0.010 0.250 
Fever 25 (35.2) 14 (33.3) 0.839 > 0.999 
Fatigue 23 (32.4) 9 (21.4) 0.211 > 0.999 
Neck pain 17 (23.9) 3 (7.1) 0.024 0.552 
Skeletal pain 15 (21.1) 2 (4.8) 0.019 0.456 
Vomiting 14 (19.7) 10 (23.8) 0.607 > 0.999 
Photophobia 10 (14.1) 4 (9.5) 0.477 > 0.999 
Anorexia 8 (11.3) 6 (14.3) 0.638 > 0.999 
Malaise 7 (9.9) 5 (11.9) 0.759 > 0.999 
Nausea 7 (9.9) 5 (11.9) 0.759 > 0.999 
Abdominal pain 7 (9.9) 1 (2.4) 0.254 > 0.999 
Arthralgia 4 (5.6) 2 (4.8) > 0.999 > 0.999 
Irritability 3 (4.2) 2 (4.8) > 0.999 > 0.999 
Sore throat 3 (4.2) 1 (2.4) > 0.999 > 0.999 
Otalgia 3 (4.2) 1 (2.4) > 0.999 > 0.999 
Myalgia 3 (4.2) 0 (0.0) 0.293 > 0.999 
Diarrhea 2 (2.8) 1 (2.4) > 0.999 > 0.999 
Diplopia 2 (2.8) 0 (0.0) 0.529 > 0.999 
Drowsiness 1 (1.4) 4 (9.5) 0.063 > 0.999 
Behavioral changes 1 (1.4) 2 (4.8) 0.554 > 0.999 
Chest pain  1 (1.4) 0 (0.0) > 0.999 > 0.999 
Dizziness 1 (1.4) 0 (0.0) > 0.999 > 0.999 
Micropsia 1 (1.4) 0 (0.0) > 0.999 > 0.999 
Hallucinations 0 (0.0) 1 (2.4) 0.372 > 0.999 
1Number of patients (%), IQR- interquartile range, padj - Holm's adjusted p value 
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5.3.3. Clinical signs  
Regarding the clinical signs at the initial examination, positive meningeal signs were more 
often found in children infected with B. garinii, while multiple EM was significantly more 
common in children infected with B. afzelii (Table 4). One patient infected with B. afzelii had 
bilateral lymphocytoma. 
 
Table 4: Clinical findings at initial examination of children with Lyme neuroborreliosis caused 
by B. garinii and B. afzelii. 
 B. garinii B. afzelii p padj 
No. of patients 71 42   
Abnormal clinical findings1     
Positive meningeal signs 49 (69.0) 16 (38.1) 0.001 0.019 
Peripheral facial palsy 26 (36.6) 8 (19.0) 0.049 0.833 
Temperature ≥380C 20 (28.2) 9 (21.4) 0.428 > 0.999 
Multiple erythema migrans 13 (18.3) 19 (45.2) 0.002 0.036 
Erythematous throat 12 (16.9) 3 (7.1) 0.140 > 0.999 
Lymphadenopathy 9 (12.7) 2 (4.8) 0.207 > 0.999 
Solitary erythema migrans 9 (12.7) 2 (4.8) 0.207 > 0.999 
Tremor 8 (11.3) 1 (2.4) 0.150 > 0.999 
Conjunctivitis 7 (9.9) 5 (11.9) 0.759 > 0.999 
Systolic murmur 3 (4.3) 4 (9.5) 0.421 > 0.999 
Otitis 3 (4.2) 1 (2.4) > 0.999 > 0.999 
Painful muscles on palpation 2 (2.8) 0 (0.0) 0.529 > 0.999 
Hepatomegaly  1 (1.4) 1 (2.4) > 0.999 > 0.999 
Abdominal pain on palpation 1 (1.4) 0 (0.0) > 0.999 > 0.999 
Voiding disturbances 1 (1.4) 0 (0.0) > 0.999 > 0.999 
Lymphocytoma 0 (0.0) 1 (2.4) 0.372 > 0.999 
Dehydration 0 (0.0) 1 (2.4) 0.372 > 0.999 
Splenomegaly 0 (0.0) 1 (2.4) 0.372 > 0.999 
Coxitis 0 (0.0) 1 (2.4) 0.372 > 0.999 
1Number of patients (%), padj – Holm's adjusted p value 
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5.4. Laboratory evaluation 
 
5.4.1. Laboratory evaluation of blood 
Laboratory blood findings upon admission are shown in Table 5. In both groups, there were 
only a few patients with abnormal findings and no pattern of abnormal findings (e.g. 
cytopenia) can be described. There were no statistically significant differences between 
patients infected with B. garinii and B. afzelii.  
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Table 5: Laboratory blood findings upon admission in children with Lyme neuroborreliosis 
caused by B. garinii and B. afzelii. 
 B. garinii B. afzelii p  padj 
No. of patients 71 42   
Erythrocyte sedimentation rate 
Median (IQR) (mm/h) 
12 (9) 11 (16) 0.680 >0.999 
High erythrocyte sedimentation rate1 
(> 20 mm/h) 
7/47 (14.9) 5/18 (27.8) 0.288 >0.999 
C-reactive protein  
Median (IQR) (mg/l)* 
12.0 (5.0) 24.0 (25.0) 0.036 0.612 
High C-reactive protein1 
(> 8 mg/l) 
5/69 (7.2) 9/41 (21.9) 0.025 0.504 
White blood cell count  
Median (IQR) (×109/l) 
7.9 (3.7) 8.9 (5.4) 0.140 >0.999 
High white blood cell count1,2 1/71 (1.4) 2/41 (4.9) 0.553 >0.999 
Low white blood cell count1,2 4/71 (5.6) 1/41 (2.4) 0.651 >0.999 
Platelet count  
Median (IQR) (×109/l) 
331 (108) 369 (119) 0.699 >0.999 
Low platelet count1,2  0/71 (0) 0/41 (0) / / 
Bilirubin total  
Median (IQR) (µmol/l) 
8 (6) 7 (5) 0.593 >0.999 
High bilirubin total1  5/55 (9.1) 5/34 (14.7) 0.504 >0.999 
Bilirubin conjugated  
Median (IQR) (µmol/l) 
 
1 (2) 
 
2 (4) 
 
0.024 
 
0.504 
High bilirubin conjugated1 6/71 (8.5) 10/42 (23.8) 0.024 0.504 
High liver enzymes1,2  
(AST and/or ALT and/or ɣ-GT) 
9/60 (15) 7/37 (18.9) 0.613 >0.999 
Serum proteins 
Median (IQR) (g/l) 
79.0 (7.0) 75.5 (7.0) 0.026 0.504 
High serum proteins1,2 9/24 (37.5) 1/14 (7.1) 0.059 0.885 
Serum albumin 
Median (IQR) (g/l) 
47.0 (7.0) 47.0 (7.0) 0.413 >0.999 
High serum albumin1,2 7/67 (10.4) 8/39 (20.5) 0.152 >0.999 
Serum IgG 
Median (IQR) (g/l) 
11.10 (4.10) 10.10 (3.40) 0.049 0.784 
High serum IgG1,2 8/67 (11.9) 2/39 (5.1) 0.318 >0.999 
Serum IgM 
Median (IQR) (g/l) 
1.12 (0.53) 0.99 (0.71) 0.192 >0.999 
High serum IgM1,2 3/50 (6.0) 1/35 (2.9) 0.640 >0.999 
1Number of abnormal findings/number of examined patients (%), 2according to patient’s 
age, * - calculated to positive values, AST – aspartate aminotransferase, ALT – alanine 
aminotransferase, ɣ-GT – gamma-glutamyl transpeptidase, IQR – interquartile range, Ig - 
immunoglobulins, IQR- interquartile range, padj – Holm's adjusted p value 
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5.4.2. Laboratory evaluation of CSF 
CSF findings in children with B. garinii and B. afzelii isolated from CSF are shown in Table 6. 
One patient from the B. garinii and one patient from the B. afzelii group had CSF red blood 
cells > 700 x 106 cells/l and were excluded from these findings. Laboratory data on CSF 
findings were not available for one patient from the B. afzelii group. 
 
Children infected with B. garinii had more frequent lymphocytic predominance and elevated 
QAlb compared to children infected with B. afzelii.  
 
Furthermore, pleocytosis was present in 96/110 (87.3%) patients. 91/110 (82.7%) patients 
had lymphocytic predominance, while 5/110 (4.5%) patients had neutrophil predominance 
with median CSF white blood cell count 373 x 106 cells/l (IQR 268-374 x 106 cells/l) and 
median CSF neutrophil count 203 x 106 cells/l (IQR 187-304 x 106 cells/l). Additionally, 2/110 
(1.8%) patients had pleocytosis >1000 x 106 cells/l and both of them had lymphocytic 
predominance. Notice that 14/110 (12.7%) patients had no pleocytosis. 
 
Total IgM intrathecal production was detected in 40/63 (63.5%) patients, followed by IgA in 
16/63 (25.4%), and IgG in 4/64 (6.3%). There was no difference between the two etiologic 
groups.  
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Table 6: Cerebrospinal fluid findings in children with Lyme neuroborreliosis caused by 
B. garinii and B. afzelii. 
 B. garinii B. afzelii p padj 
No. of patients 70 40   
White blood cell count 
Median (IQR) (×106 cells/l) 
253.5 (81.5-350.8) 93.5 (5.0-292.8) 0.017 0.255 
Pleocytosis1 
(≥5 ×106 cells/l) 
66/70 (94.3) 30/40 (75.0) 0.004 0.068 
Lymphocytes 
Median (IQR) (×106 cells/l) 
218.5 (68.0-291.8) 56.0 (2.0-225.5) 0.004 0.068 
Lymphocytic 
predominance1 
65/70 (92.9) 26/40 (65.0) 0.001 0.008 
Glucose concentration 
Median (IQR) (mmol/l) 
2.80 (2.50-3.00) 2.95 (2.70-3.23) 0.048 0.432 
Decreased glucose 
concentration1 
(<½ blood glucose) 
29/67 (43.3) 15/40 (37.5) 0.556 > 0.999 
Total protein level 
Median (IQR) (g/l) 
0.46 (0.35-0.62) 0.30 (0.23-0.59) 0.025 0.300 
 
Elevated total protein 
level1 
(≥0,45 g/l) 
35/70 (50.0) 15/40 (37.5) 0.205 > 0.999 
Albumin level 
Median (IQR) (mg/l) 
276.0 (213.0-394.0) 183.0 (126.25-371.0) 0.018 0.255 
Elevated albumin level1 
(≥300 mg/l) 
31/65 (47.7) 12/37 (32.4) 0.133 0.896 
Total IgG level 
Median (IQR) (mg/l) 
37.5 (21.9-56.4) 20.2 (12.1-49.0) 0.022 0.286 
Elevated total IgG level1 
(≥40 mg/l) 
31/67 (46.3) 11/37 (29.7) 0.100 0.800 
Total IgM level 
Median (IQR) (mg/l) 
2.9 (1.5-8.0) 1.9 (0.5-6.8) 0.314 > 0.999 
Elevated total IgM level1 
(≥0,7 mg/l) 
42/49 (85.7) 18/32 (56.3) 0.003 0.054 
QAlb 
Median (IQR) (×10-3) 
5.64 (4.21-8.29) 3.98 (2.62-7.45) 0.027 0.300 
Elevated QAlb1,2 50/62 (80.6) 18/36 (50.0) 0.002 0.038 
QIgG 
Median (IQR) (×10-3) 
3.53 (2.31-5.17) 1.93 (1.32-4.49) 0.039 0.390 
Elevated QIgG1,2 2/37 (5.4) 4/27 (14.8) 0.231 > 0.999 
QIgM 
Median (IQR) (×10-3) 
2.08 (0.99-7.42) 1,00 (0.19-4.97) 0.128 0.896 
Elevated QIgM1,2 24/36 (66.7) 16/27 (59.3) 0.546 > 0.999 
1Number of abnormal findings/number of examined patients (%), 2according to patient’s 
age, Ig - immunoglobulins, QAlb (IgG, IgM)- CSF/serum albumin (IgG, IgM) quotient, IgGIF (A, M) – 
fraction of intrathecally produced unspecific immunoglobulins G (A, M), IQR- interquartile 
range, padj – Holm's adjusted p value 
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Table 6: Continued. Cerebrospinal fluid findings in children with Lyme neuroborreliosis 
caused by B. garinii and B. afzelii. 
 B. garinii B. afzelii p padj 
No. of patients 70 40   
IgGIF 
Median (IQR) (%) 
0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.090 0.540 
Positive IgGIF1 
(>10%) 
1/37 (2.7) 3/27 (11.1) 0.302 >0.999 
IgAIF  
Median (IQR) (%) 
0.0 (0.0-14.8) 0.0 (0.0-3.5)  0.408 >0.999 
Positive IgAIF1 
(>10%) 
10/36 (27.8) 6/27 (22.2) 0.772 >0.999 
IgMIF  
Median (IQR) (%) 
44.4 (0.0-64.1) 37.0 (0.0-63.3) 0.408 >0.999 
Positive IgMIF1 
(>10%) 
24/36 (66.7) 16/27 (59.3) 0.603 >0.999 
1Number of abnormal findings/number of examined patients (%), 2according to patient’s 
age, Ig - immunoglobulins, QAlb (IgG, IgM)- CSF/serum albumin (IgG, IgM) quotient, IgGIF (A, M) – 
fraction of intrathecally produced unspecific immunoglobulins G (A, M), IQR- interquartile 
range, padj – Holm's adjusted p value 
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5.5. Microbiological evaluation 
 
5.5.1. Isolation of Borrelia burgdorferi sensu lato from blood 
Upon admission, in 2/41 (4.9%) patients from the B. afzelii group, B. afzelii was isolated from 
blood. Both patients had multiple erythema migrans. In the B. garinii group, there weren’t 
any positive blood cultures (0/65, 0.0%). The difference in proportion of patients with 
positive blood cultures between the two groups of patients was not statistically significant 
(p=0.147). 
 
5.5.2. Determination of borrelial antibodies 
The results of determination of specific borrelial antibodies in acute phase serum and CSF 
and the results of therefrom calculated AI are shown in Table 7. Specific borrelial antibodies 
in acute phase serum and CSF were detected in up to 12.5% and up to 77.8% of patients by 
IFA and LIAISON, respectively. Antibody index was positive in up to 10.0% and up to 71.4% of 
patients when calculated using IFA and LIAISON results, respectively. There was no 
statistically significant difference between these results for the patients infected with 
B. garinii compared to patients infected with B. afzelii.  
 
Comparing the proportions of patients with positive results for all these categories, 
regardless of the etiologic group, when IFA or LIAISON was used for determination of specific 
borrelial antibodies, the difference was statistically significant (padj<0.001), with LIASION 
giving more positive results. 
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Of the 14/110 (12.7%) patients from both groups with no CSF pleocytosis, 9 patients had 
multiple EM, 2 had PFP, 1 had symptoms/signs of meningitis, 1 had bilateral lymphocytoma, 
and 1 had only fever. No patient/13 (0.0%) had IgM and one patient/13 (7.7%) from the 
B. afzelii group with multiple EM had IgG antibodies to B. burgdorferi sensu lato in the acute 
phase serum, as determined by IFA. None/14 (0.0%) patients had IgM or IgG antibodies to 
B. burgdorferi sensu lato present in CSF, as determined by IFA. LIAISON was not used for the 
determination of borrelial antibodies in acute phase serum or CSF in any of these patients.  
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Table 7: Borrelial IgM and IgG in acute phase serum and CSF, and IgM and IgG antibody 
index in children with Lyme neuroborreliosis caused by B. garinii and B. afzelii. 
 
B. garinii B. afzelii p padj 
No. of patients 70 40    
Positive IgM antibodies to B. burgdorferi 
sensu lato in serum 
    
IFA1 0/68 (0.0) 1/39 (2.6) 0.365 >0.999 
LIAISON1 5/20 (25.0) 7/13 (53.8) 0.142 >0.999 
Positive IgG antibodies to B. burgdorferi 
sensu lato in serum 
    
IFA1 7/68 (10.3) 2/39 (5.1) 0.482 >0.999 
LIAISON1 10/20 (50.0) 7/13 (53.8) 1.000 >0.999 
Positive IgM antibodies to B. burgdorferi 
sensu lato in CSF 
    
IFA1 0/69 (0.0) 1/40 (2.5) 0.375 >0.999 
LIAISON1 14/18 (77.8) 5/10 (50.0) 0.210 >0.999 
Positive IgG antibodies to B. burgdorferi 
sensu lato in CSF 
    
IFA1 1/69 (1.4) 5/40 (12.5) 0.027 0.486 
LIAISON1 12/18 (66.7) 5/10 (50.0) 0.444 >0.999 
Elevated IgM B. burgdorferi sensu lato 
antibody index 
(normal ≤1.4) 
    
IFA1 0/68 (0.0) 1/40 (2.5) 0.370 >0.999 
LIAISON1 10/14 (71.4) 5/10 (50.0) 0.403 >0.999 
Elevated IgG B. burgdorferi sensu lato 
antibody index 
(normal ≤ 1.4) 
    
IFA1 1/69 (1.5) 3/39 (7.7) 0.133 0.798 
LIAISON1 11/16 (68.8) 5/10 (50.0) 0.425 >0.999 
1Number of abnormal findings/number of examined patients (%), Ig – immunoglobulins, IFA 
– immunofluorescent assay, LIAISON - indirect chemiluminescence immunoassay, padj – 
Holm's adjusted p value 
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5.6. Classification performance analysis 
The results of classification performance obtained by five different machine-learning 
classifiers are summarized in Table 9. Among them, the random RF classifier achieved the 
best score across all performance measures and CT exhibited the worst performance. 
 
Table 9: Classification performances obtained by five machine-learning classifiers to classify 
between B. garinii and B. afzelii samples. 
Machine learning classifier Accuracy Sensitivity Specificity AUCROC 
kNN (SD) 0.64 (0.03) 0.52 (0.05) 0.70 (0.02) 0.61 (0.02) 
CT (SD) (worst performance) 0.59 (0.04) 0.45 (0.05) 0.68 (0.03) 0.58 (0.06) 
RF (SD) (best performance) 0.67 (0.03) 0.56 (0.03) 0.74 (0.02) 0.72 (0.03) 
GBM (SD) 0.67 (0.03) 0.56 (0.03) 0.74 (0.03) 0.69 (0.03) 
XGBoost (SD) 0.66 (0.03) 0.54 (0.03) 0.75 (0.03) 0.70 (0.03) 
Mean performance 0.65 0.53 0.72 0.66 
kNN - k-nearest neighbors, CT - classification tree, RF - random forest, GBM - gradient 
boosting machine, XGBoost - extreme gradient boosting, SD - standard deviation 
 
In addition to performance evaluation, the relative importance of chosen variables that 
contribute to statistical learning were examined. The RF model had the best performance 
and was selected as a baseline. The variable for classification between B. garinii and B. afzelii 
with the highest relative importance score was CSF lymphocyte concentration, followed by 
CSF albumin level, and CSF white blood cell count. Positive IFA IgG antibodies to 
B. burgdorferi sensu lato in serum had the lowest relative importance score (Table 10). 
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Table 10: Relative importance score of classification for the chosen variables to classify 
between B. garinii and B. afzelii samples. 
Chosen variables Relative importance score 
CSF lymphocyte concentration 100.00 
CSF albumin level 91.93 
CSF white blood cell count 75.01 
Duration of signs/symptoms before admission 72.98 
CSF total protein level 71.93 
Age 69.15 
Signs of meningitis as the first sign/symptom noticed 23.53 
Positive IFA IgG antibodies to B. burgdorferi sensu lato in CSF 20.50 
Erythema migrans as the first sign/symptom noticed 19.12 
Associated symptom 17.58 
Pleocytosis 14.65 
Gender - male 7.33 
Peripheral facial palsy as the first sign/symptom noticed 6.82 
Positive IFA IgG antibodies to B. burgdorferi sensu lato in serum 0.00 
IFA - immunofluorescent assay, IgG – immunoglobulin G 
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6. DISCUSSION 
 
LNB develops when the borreliae reach the CNS during the process of dissemination (1, 47). 
The clinical picture of LNB in children differs from that in adults (1, 45, 48, 56). Furthermore, 
the data on the etiology of LNB in children and on the influence of B. burgdorferi sensu lato 
species on clinical presentation in the literature is scarce (14, 54, 55). We were able to carry 
out this study because LB in Slovenia is endemic (4) and because we have a research-
oriented management of patients with LB at our medical center. For this reason, the current 
study was designed (I) to identify the species of borreliae that cause LNB in children in 
Slovenia and (II) to determine the influence of B. burgdorferi sensu lato species isolated from 
CSF on demographic, clinical, and laboratory findings.   
 
In previous years, at the same medical center, prospective studies have been conducted in 
children with signs and symptoms suggestive of LB in which the isolation rate of 
B. burgdorferi sensu lato from CSF has been established. B. burgdorferi sensu lato species 
was also determined in some of these studies. Lyme meningitis was diagnosed in 41/122 
(34%) of children treated in hospital due to serous meningitis, while 15/122 (12.3%) had 
B. burgdorferi sensu lato present in CSF (100). In 29/52 (56%) of Slovenian children with 
acute PFP, LB was established. In 7/51 (13.7%) of these patients, B. burgdorferi sensu lato 
was isolated from CSF and B. garinii was the only identified species (7/7) (54). Furthermore, 
55/214 (25.7%) children with multiple EM had pleocytosis and 8/199 (4%) of them had 
B. burgdorferi sensu lato present in CSF. In these patients, B. afzelii (BaMla1) and B. garinii 
(BgMlg2) were determined in 5/8 and in 1/8 patients, respectively, while in 2/8 patients, 
borreliae were undetermined (55). Tick-borne illness was diagnosed in 28/53 (53%) of 
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children with febrile illness after a tick bite, and 13/53 (24.5%) of these had LB. Furthermore, 
4/53 (7.6%) of these patients had B. burgdorferi sensu lato isolated from CSF (88). 
 
Within the period of 17 years of the present study, in 153 children, B. burgdorferi sensu lato 
was isolated from CSF. In 40/153 (26.1%) of patients, the borreliae did not grow well enough 
to enable species identification by MluI-LRFP. In these patients, PCR was used for 
identification. Since the identification of isolates using the PCR method can yield false-
positive results due to accidental contamination (101), we deliberately excluded these 
patients from further analysis.  
 
The remaining 113/153 (73.9%) patients who had B. burgdorferi sensu lato species identified 
by MluI-LRFP were included in further analysis. In 71/113 children (62.8%) B. garinii (Mlg2 - 
67, Mlg4 - 4), and in 42/113 (37.2%) B. afzelii (Mla1) were isolated from CSF. Since these 
were all consecutive patients treated in the one and only regional hospital, it can be 
deduced that in this area, LNB in children is most frequently caused by B. garinii, followed by 
B. afzelii.  
 
B. garinii caused LNB in our set of patients more often than B. afzelii, which raises questions 
about the culturing of borreliae. The cultivation rate of borreliae from CSF is 10-30% (101–
103) and it is not clear whether sensitivity of culture for different species of borreliae is the 
same (101). Additionally, once the patient’s specimen reaches the laboratory, contamination 
is possible (101). However, B. burgdorferi sensu lato culture from the patient’s material is 
still the gold standard for specificity in the laboratory diagnosis of LB (86). The isolation of 
borreliae from CSF and species identification for the present study, as in the previous studies 
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in our medical center, was performed at a well-established specialized and research-
oriented laboratory (21, 52, 104, 105). Moreover, there was only one positive CSF culture in 
children every five to six weeks on average during the study period. We did not observe any 
cluster cases with the same isolation and seasonality was well observed during the annual 
distribution of cases. For this reason, while contamination of these specimens is possible, we 
believe it to be very unlikely.    
 
Our results support the findings of Strle et al. at the same medical center, which looked at 
consecutive adult patients with LNB, where B. garinii was isolated in 23/36 (63.9%, Mlg2 - 
14, Mlg3 - 4, Mlg4 - 4, Mlg7 - 1), B. afzelii in 10/36 (27.8%, Mla1) and B. burgdorferi in 3/36 
(8.3%) CSF specimens (52). One difference is that the B. garinii subtypes in our group were 
less heterogeneous and the subtypes Mlg3 and Mlg7 were not isolated. Our results also 
support the findings of other studies performed at the same medical center, in which 
B. garinii was isolated from CSF as a cause of LNB more often than B. afzelii (24, 53, 104), 
and two European studies in which the most frequently detected borreliae in CSF by PCR 
was B. garinii (14, 17). In our series, B. burgdorferi was not isolated from CSF in any of the 
patients. B. burgdorferi was isolated from CSF in the above-mentioned study by Strle et al. 
(52) and detected in other European studies as well (15, 17, 21). 
 
Most cases of LNB in children in our study occurred from May to August and fewer from 
September to April. This supports the findings of other European studies (54, 58, 59, 106–
108) and North American studies (109). Our patients reported tick bites with similar 
frequency (42.5%) as patients in other European studies (35-77%) (58, 59, 106–108, 110), 
but more often than in North American studies (10-25%) (57, 109). There was no 
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predilection as to the site of the tick bite. This does not corroborate the findings of the 
Swedish study by Södermark et al., in which in 72% of children with LNB, the location of the 
bite was in the head and neck area, in 24%, it was below the neck, and in 4%, it was in both 
regions (108). Regarding tick bite location, we could not differentiate patients with LNB 
caused by B. garinii from patients with LNB caused by B. afzelii.  
 
The median duration of the first signs/symptoms of disease upon admission of our patients 
was 4 days, which is shorter than reported in other European studies (median 7-14 days) 
(107, 108, 111). In these studies, a positive B. burgdorferi sensu lato CSF culture was not one 
of the inclusion criteria. The difference in the median duration of the first signs/symptoms of 
the disease can thus be explained by the fact that we only included patients with positive 
CSF culture, and by more successful isolations from patients with early disease (EM or early 
LNB) (101). To a lesser extent, the relatively short duration of the first sign/symptom in our 
series could be due to strong awareness of the disease or good availability of pediatric 
infectious diseases specialists in our country. 
 
The clinical picture of LNB in children in Europe and North America has already been well 
documented. In Europe, where the main causes of LB are B. garinii, B. afzelii, and 
B. burgdorferi (1, 2, 14–26), 59-71% of children with LNB have PFP, 50-69% headache, 29-
46% neck pain/stiffness, 19-46% fever, 39-86% fatigue, 26-52% malaise, 18-60% loss of 
appetite, 13% EM, 18% lymphocytoma, 23% gastrointestinal symptoms, 18% weight loss, 
14% arthralgia, 11% back pain or pain in extremities, 9% sensory disturbances, and 6-12% 
behavioral changes (107, 108, 110–112). In North America, where LB is caused almost 
exclusively by B. burgdorferi (1, 2), as well as in Europe, the most common neurologic 
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manifestations in children with LB are meningitis and PFP; radiculopathy is infrequent (1, 45, 
48, 113). In North America, Lyme meningitis in children is accompanied by positive 
meningeal signs in 71%, gastrointestinal symptoms in 58%, history of fever in 41% and 
arthralgia in 30% (109, 114). Over 80% of children with PFP due to LB in North America have 
systemic symptoms (115). However, our group of patients is a rather select one and we have 
not performed any comparison of our results with all cases of LNB in children. As such, our 
results do not describe a clinical picture of LNB in children in general. For this reason, these 
results cannot be compared to those of the above-mentioned studies.  
 
Our results do offer a comparison of the clinical picture of LNB in children caused by 
B. garinii to the one caused by B. afzelii. Comparisons of this kind have been very scarce in 
the literature (14). These are the most important results of the present study. We discovered 
that the two etiologic groups differ in the first perceived sign/symptom of the disease 
(padj=0.005). Patients with B. garinii isolated from CSF noticed symptoms of meningitis 
(57.7% vs. 28.6%, padj=0.012), and patients with B. afzelii noticed erythema migrans (45.2% 
vs. 21.1%, padj=0.021), more frequently as the first sign/symptom. A group of “other first 
signs/symptoms”, which include fever only, bilateral lymphocytoma, arthralgia, and eating 
disorder, was more frequent in patients infected with B. afzelii (9.5% vs. 0.0%, padj=0.034). 
However, in our study, upon admission, patients infected with B. garinii did not report 
symptoms suggestive of CNS involvement (headache, neck pain, vomiting, nausea, 
irritability, drowsiness, behavioral changes, dizziness, visual symptoms) or any other 
symptoms more often than patients infected with B. afzelii. During the clinical examination 
of patients infected with B. garinii, except for positive meningeal signs (69.0% vs. 38.1%, 
padj=0.019), other clinical signs suggestive of CNS involvement (PFP, tremor, voiding 
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disturbances) were not more frequent. Patients infected with B. afzelii had more frequent 
multiple EM (45.2% vs. 18.3%, padj=0.036). This is in concordance with the difference 
between the two groups regarding the first signs/symptoms of the disease. In our series, 
none of the patients had Bannwarth syndrome. Thus, our results show that the signs and 
symptoms of LNB in children caused by B. garinii are not more suggestive of CNS 
involvement. These are the major findings of our study, which represent very novel results.  
 
These results, regarding signs and symptoms of children with LNB, do not support the 
findings of Strle et al., which found that in cases of early LNB in adult patients, B. garinii 
causes more typical disease (Bannwarth syndrome) and LNB caused by B. afzelii is less 
specific (52). This difference, when compared to our results, could be explained by the fact 
that our study included only children and LNB in children differs from disease presentation in 
adults (110, 116). However, our findings do support the very recent findings of Barstad et al. 
who found that children with LNB caused by B. garinii did not have a distinct clinical picture 
(14).  
 
In children with LNB, the European and North American studies report median pleocytosis of 
129-378 x 106 cells/l (108, 110, 111) and 62 x 106 cells/l (109), and of mononuclear 
predominance with median values of 97-98% (106, 108) and 91-96% (109, 117, 118), 
respectively. European authors report elevated CSF albumin (median 293 mg/l) (108) and 
elevated CSF protein values (median 45-54 mg/dl) (58, 106) in 66.6% (58) of children with 
LNB. Our results support these findings. Additionally, our CSF laboratory results show more 
frequent lymphocytic predominance (92.9% vs. 65.0%, padj=0.008) and more frequent 
dysfunction of blood brain barrier (elevated QAlb 80.6% vs. 50.0%, padj=0.038) in children with 
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LNB caused by B. garinii compared to LNB caused by B. afzelii. Patients with B. garinii 
infection had a median CSF white blood cell count higher than patients with B. afzelii 
infection (253.5x106 cells/l vs. 93.5x106 cells/l, padj=0.323), but the difference was not 
statistically significant. Similarly, in adult patients, Strle et al. found that patients with 
B. garinii isolated from CSF had significantly higher median CSF white blood cell values, more 
frequent lymphocytic predominance, and more frequently elevated CSF protein 
concentrations (52). Therefore, our results support their findings, with the only difference 
being that the difference between the children infected with B. garinii and children infected 
with B. afzelii is less pronounced. This could be due to the same median duration of 
symptoms before LP in our two groups of patients (4 days). In the study of Strle et al. this 
period for patients infected with B. afzelii was 7.5 months and for patients infected with 
B. garinii, 19 days, but the difference was not statistically significant (52). Thus, inflammation 
seems to be less pronounced in both children and adults with B. afzelii compared to patients 
with B. garinii isolated from CSF.  
 
The value of our results is also in the description of immunological response in children with 
B. burgdorferi sensu lato isolated from CSF, even though there was no statistically significant 
difference between the two etiologic groups. When evaluating these results, one needs to 
keep in mind the median duration of symptoms of 4 days (B. garinii group IQR 2.0-6.0 days, 
B. afzelii group IQR 1.0-10.8 days), when blood and CSF samples were taken.  
 
In our study, the intrathecal production of total IgM was most frequently detected (63.5%), 
followed by production of total IgA (25.5%) and total IgG (6.3%). These results support the 
findings of Arnež at al. in children with acute PFP with median duration of symptoms of 2 
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days, where the same pattern, characteristic of early LNB, was observed (IgM in 55%, IgA in 
15%, and IgG in 0%) (54).  
 
Furthermore, IFA and/or LIAISON were used to evaluate the specific immunologic response 
in blood and CSF to B. burgdorferi sensu lato. Borrelial specific IgM and IgG were present in 
serum in 12.0% and 22.2% respectively. Both IgM and IgG were present in CSF in 17.4% of 
patients. Intrathecal synthesis of specific borrelial IgM and IgG antibodies was present in 
13.9% and 16.5%, respectively. In a study by Cerar et al., in which the IDEIA test and LIAISON 
were used for the detection of borrelial antibodies, the intrathecal production of specific 
borrelial IgM antibodies (50.0%) and IgG (44.1%) in adult patients with clinically evident LNB 
was present more frequently, but the median duration of symptoms was longer (10 days, 
range 2-90 days) (119). On the other hand, a study by Stanek et al., in which CLA and two 
ELISA tests were used for the detection of borrelial antibodies in adult patients, showed that 
B. burgdorferi sensu lato specific IgM, and IgG were not produced intrathecally during the 
first week of illness. IgG intrathecal production was detectable at the end of the first week 
and IgM intrathecal production was heterogeneous (120). According to the above-
mentioned results, the intrathecal production of specific borrelial antibodies in children with 
LNB in our study is most probably present earlier, and a study describing humoral immune 
response day by day in children could elucidate this.  
 
As a side result of our serological findings, the borrelial antibodies in serum and CSF in our 
set of patients were more frequently detected by LIAISON than by IFA (padj<0.001). Similar 
differences in detecting borrelial antibodies by different microbiological methods have been 
described before (93, 119, 120). This supports and adds to the findings of Cerar et al., who 
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showed that LIAISON is more sensitive than IFA for detection of borrelial IgM and IgG 
antibodies in serum of patients with early Lyme borreliosis, but not in patients with Lyme 
neuroborreliosis and chronic Lyme borreliosis (93). It would be in one’s interest to know how 
well these two tests perform at the initial evaluation and in the follow up of patients with LB. 
For example, such knowledge could help us resolve diagnostic dilemmas even in our subset 
of patients with isolated B. burgdorferi sensu lato from CSF but with no pleocytosis (14/110, 
12.7%). However, the serum and CSF samples of these patients were not tested by LIAISON, 
because LIAISON has only been routinely used in samples of children at our medical center 
since 2013. Diagnosis was established only by isolation of B. burgdorferi sensu lato from CSF 
only in 4/14 patients (fever only 1, signs/symptoms of meningitis 1, PFP 2). This subset of 
patients also stresses the importance of performing culture of CSF to B. burgdorferi sensu 
lato even though the method has a low yield and the results take 2-3 months (1, 104, 121).  
 
Not unexpectedly, B. burgdorferi sensu lato in our patients was also isolated from blood. 
Both isolates were B. afzelii in patients with multiple EM and with B. afzelii isolated from 
CSF. Similarly, in a study by Arnež et. al, in children with PFP, there were 3/52 (5.8%) isolates 
from blood: one isolate was B. afzelii and two were undetermined (54). These findings 
support the possible hematogenous route of dissemination in patients infected with 
B. afzelii.  
 
The two relatively large1 groups of patients with determined B. burgdorferi sensu lato 
species offered us a possibility to perform machine-learning analysis (i.e., class classification 
task). The analysis revealed the most important variable for classification between patients 
                                                          
1 A small group of patients is a real treasure for a physician, a nice challenge for a statistician, 
and a real headache for a mathematician. 
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infected with B. garinii and those infected with B. afzelii to be CSF lymphocyte 
concentration, followed by CSF albumin level, and CSF white blood cell count. We have not 
found any similar analysis in the literature. Machine-learning offers a tool to differentiate 
between the two groups of patients without the demanding culturing procedure and the 
microbiological identification of borreliae. The differentiation between the two groups alone 
is not important for the treatment of the patients, but for obtaining more distinctions that 
can subsequently offer us directions for further epidemiologic, microbiologic, pathogenetic, 
and immunologic research. However, the algorithm is robust and it only gives us the 
approximate relative importance of classification for the chosen variables.  
 
The results of our study present ideas for further research. The apparent direction would be 
to follow-up with our patients and describe signs, symptoms, and serological findings, which 
would then be compared between the two etiologic groups. Furthermore, due to the low 
percentage of children with typical features of LB in the present study (30.1% of patients had 
PFP, 28.3% had multiple EM), patients with positive CSF B. burgdorferi sensu lato culture, 
who were without PFP and/or multiple EM, could be compared to patients with serous 
meningitis who have very similar presentation. This would be of clinical importance, because 
LNB demands antibiotic treatment. Since the inflammation in CSF is more pronounced in 
children with B. garinii infection who otherwise don’t have a distinct clinical picture of CNS 
infection, other factors influencing clinical presentation, including host factors, should be 
considered. Therefore, another research direction could be the description of humoral 
immune response in children with LNB. 
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The present study is mono-centric and the epidemiological findings are only relevant to the 
central part of Slovenia. Another limitation is the long study period, during which micro 
changes in clinical assessment of patients and/or undetectable changes in laboratory 
environment/procedures could arise that could inadvertently affect our results.  
 
According to our knowledge, this is the largest study in Europe and North America in 
children with B. burgdorferi sensu lato isolated from CSF. The present study has revealed 
that, in Slovenia, LNB in children is more often caused by B. garinii, followed by B. afzelii. The 
analysis of clinical presentation revealed that the signs and symptoms of LNB in children 
caused by B. garinii are not more suggestive of CNS involvement compared to children 
infected with B. afzelii. However, the CSF laboratory results show more pronounced 
inflammation in children infected with B. garinii compared to children infected with 
B. afzelii. Thus, the clinical presentation of Lyme neuroborreliosis in children depends on 
B. burgdorferi sensu lato species. 
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7. CONCLUSIONS  
1. In Slovenia, LNB in children is most often caused by B. garinii, followed by B. afzelii. 
2. Most cases of LNB in children occurred from May to August. 
3. The clinical presentation of Lyme neuroborreliosis in children depends on B. burgdorferi 
sensu lato species. 
 As the first sign/symptom, patients with B. garinii isolated from CSF noticed 
symptoms of meningitis and patients with B. afzelii noticed EM more often. 
 Patients infected with B. garinii did not report symptoms suggestive of CNS 
involvement more often than patients infected with B. afzelii. 
 Upon clinical examination, in patients infected with B. garinii, except for positive 
meningeal signs, other clinical signs suggestive of CNS involvement were not more 
frequent. Patients infected with B. afzelii had more frequent multiple EM. 
 CSF laboratory results show more frequent lymphocytic predominance and more 
frequent dysfunction of blood brain barrier and CNS inflammation seems to be more 
pronounced in children infected with B. garinii compared to children infected with 
B. afzelii.  
4. In serum and CSF borrelial specific antibodies determined by IFA and/or LIAISON were 
present in up to 22.2% and 17.4%, respectively. Intrathecal synthesis of specific borrelial 
antibodies was present in up to 16.5%. 
5. The most important feature for classification between patients infected with B. garinii 
and those infected with B. afzelii is CSF lymphocyte concentration, followed by CSF 
albumin level and CSF white blood cell count. 
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8. ANSWERS TO HYPOTHESIS 
 
1. B. garinii is the main cause of LNB in children in Slovenia, as in adult patients. 
CONFIRMED 
 
2. The clinical presentation of LNB depends on the B. burgdorferi sensu lato species that 
caused it.  
CONFIRMED 
 
 
 
  
58 
 
9. REFERENCES 
1.  Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 2012; 379: 461–73.  
2.  Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JWR, et al. Lyme borreliosis. 
Nat Rev Dis Primers 2016; 2: 16090.  
3.  Sočan M, Kraigher A, Klavs I, Frelih T, Grilc E, Grgič Vitek M, et al., editors. 
Epidemiološko spremljanje nalezljivih bolezni v letu 2017. Nacionalni inštitut za javno 
zdravje 2018. Available from: http://www.nijz.si/sl/epidemiolosko-spremljanje-
nalezljivih-bolezni-letna-porocila  
4.  Strle F. Lyme borreliosis in Slovenia. Zentralbl Bakteriol 1999; 289: 643–52.  
5.  Steere AC, Malawista SE, Snydman DR, Shope RE, Andiman WA, Ross MR, et al. An 
epidemic of oligoarticular arthritis in children and adults in three Connecticut 
communities. Arthritis & Rheumatism 1977; 20: 7–17.  
6.  Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. Lyme disease-a 
tick-borne spirochetosis? Science 1982; 216: 1317–9.  
7.  Steere AC. Lyme disease. N Engl J Med 1989; 321: 586–96.  
8.  Lindgren E, Jaenson TGT. Lyme borreliosis in Europe: influences of climate and climate 
change, epidemiology, ecology and adaptation measures. WHO 2006: 35.  
9.  Kraigher A, Sočan M, Klavs I, Frelih T, Grilc E, Grgič Vitek M, et al. Epidemiološko 
spremljanje nalezljivih bolezni v Sloveniji 2013. Nacionalni inštitut za javno zdravje 
2014. Available from: http://www.nijz.si/sl/epidemiolosko-spremljanje-nalezljivih-
bolezni-letna-porocila 
10.  Kraigher A, Sočan M, Klavs I, Frelih T, Grilc E, Grgič Vitek M, et al. Epidemiološko 
spremljanje nalezljivih bolezni v Sloveniji v letu 2015. Nacionalni inštitut za javno 
zdravje 2016. Available from: http://www.nijz.si/sl/epidemiolosko-spremljanje-
nalezljivih-bolezni-letna-porocila 
11.  Kraigher A, Sočan M, Klavs I, Frelih T, Kolman J, Čakš Jager N, et al. Epidemiološko 
spremljanje nalezljivih bolezni v Sloveniji v letu 2011. Nacionalni inštitut za javno 
zdravje 2012. Available from: http://www.nijz.si/sl/epidemiolosko-spremljanje-
nalezljivih-bolezni-letna-porocila 
12.  Lyme Disease | Lyme Disease | CDC. 2019. Available from: 
https://www.cdc.gov/lyme/index.html 
13.  Schwartz AM, Hinckley AF, Mead PS, Hook SA, Kugeler KJ. Surveillance for Lyme 
Disease — United States, 2008–2015. MMWR Surveill Summ 2017; 66: 1–12.  
 
59 
 
14.  Barstad B, Quarsten H, Tveitnes D, Noraas S, Ask IS, Saeed M, et al. Direct Molecular 
Detection and Genotyping of Borrelia burgdorferi Sensu Lato in Cerebrospinal Fluid of 
Children with Lyme Neuroborreliosis. Journal of Clinical Microbiology 2018; 56: 
e01868-17.  
15.  Busch U, Hizo-Teufel C, Boehmer R, Fingerle V, Nitschko H, Wilske B, et al. Three 
species of Borrelia burgdorferi sensu lato (B. burgdorferi sensu stricto, B afzelii, and B. 
garinii) identified from cerebrospinal fluid isolates by pulsed-field gel electrophoresis 
and PCR. J Clin Microbiol 1996; 34: 1072–8.  
16.  Jungnick S, Margos G, Rieger M, Dzaferovic E, Bent SJ, Overzier E, et al. Borrelia 
burgdorferi sensu stricto and Borrelia afzelii: Population structure and differential 
pathogenicity. International Journal of Medical Microbiology. 2015; 305: 673–81.  
17.  Ornstein K, Berglund J, Bergström S, Norrby R, Barbour AG. Three Major Lyme Borrelia 
Genospecies (Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii) Identified by 
PCR in Cerebrospinal Fluid from Patients with Neuroborreliosis in Sweden. 
Scandinavian Journal of Infectious Diseases 2002; 34: 341–6.  
18.  Ornstein K, Berglund J, Nilsson I, Norrby R, Bergström S. Characterization of Lyme 
Borreliosis Isolates from Patients with Erythema Migrans and Neuroborreliosis in 
Southern Sweden. J Clin Microbiol 2001; 39: 1294–8.  
19.  Picken RN, Cheng Y, Strle F, Cimperman J, Maraspin V, Lotric-Furlan S, et al. Molecular 
characterization of Borrelia burgdorferi sensu lato from Slovenia revealing significant 
differences between tick and human isolates. Eur J Clin Microbiol Infect Dis 1996; 15: 
313–23.  
20.  Ruzić-Sabljić E, Arnez M, Lotric-Furlan S, Maraspin V, Cimperman J, Strle F. Genotypic 
and phenotypic characterisation of Borrelia burgdorferi sensu lato strains isolated 
from human blood. J Med Microbiol 2001; 50: 896–901.  
21.  Ruzić-Sabljić E, Lotric-Furlan S, Maraspin V, Cimperman J, Pleterski-Rigler D, Strle F. 
Analysis of Borrelia burgdorferi sensu lato isolated from cerebrospinal fluid. APMIS 
2001; 109: 707–13.  
22.  Ruzic-Sabljic E, Strle F, Cimperman J, Maraspin V, Lotric-Furlan S, Pleterski-Rigler D. 
Characterisation of Borrelia burgdorferi sensu lato strains isolated from patients with 
skin manifestations of Lyme borreliosis residing in Slovenia. Journal of Medical 
Microbiology 2000:47–53.  
23.  Ružić-Sabljić E, Arnež M, Logar M, Maraspin V, Lotrič-Furlan S, Cimperman J, et al. 
Comparison of Borrelia burgdorferi Sensu Lato Strains Isolated from Specimens 
Obtained Simultaneously from Two Different Sites of Infection in Individual Patients. J 
Clin Microbiol 2005; 43: 2194–200.  
24.  Ruzić-Sabljić E, Maraspin V, Lotric-Furlan S, Jurca T, Logar M, Pikelj-Pecnik A, et al. 
Characterization of Borrelia burgdorferi sensu lato strains isolated from human 
material in Slovenia. Wien Klin Wochenschr 2002; 114: 544–50.  
60 
 
25.  Ruzić-Sabljić E, Zore A, Strle F. Characterization of Borrelia burgdorferi sensu lato 
isolates by pulsed-field gel electrophoresis after MluI restriction of genomic DNA. Res 
Microbiol 2008; 159: 441–8.  
26.  Saint Girons I, Gern L, Gray JS, Guy EC, Korenberg E, Nuttall PA, et al. Identification of 
Borrelia burgdorferi sensu lato species in Europe. Zentralbl Bakteriol 1998; 287: 190–
5.  
27.  Winslow C, Coburn J. Recent discoveries and advancements in research on the Lyme 
disease spirochete Borrelia burgdorferi. F1000Research 2019; 8: 763.  
28.  Preac-Mursic V, Wilske B, Schierz G. European Borrelia burgdorferi isolated from 
humans and ticks culture conditions and antibiotic susceptibility. Zentralbl Bakteriol 
Mikrobiol Hyg A 1986; 263: 112–8.  
29.  Mysterud A, Stigum VM, Jaarsma RI, Sprong H. Genospecies of Borrelia burgdorferi 
sensu lato detected in 16 mammal species and questing ticks from northern Europe. 
Sci Rep 2019; 9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ 
PMC6434031/ 
30.  VOORDOUW MJ. Co-feeding transmission in Lyme disease pathogens. Parasitology 
2015; 142: 290–302.  
31.  Belfaiza J, Postic D, Bellenger E, Baranton G, Girons IS. Genomic fingerprinting of 
Borrelia burgdorferi sensu lato by pulsed-field gel electrophoresis. J Clin Microbiol 
1993; 31: 2873–7.  
32.  O’Connell S, Wolfs TFW. Lyme borreliosis. Pediatr Infect Dis J 2014; 33: 407–9.  
33.  Shapiro ED. Borrelia burgdorferi (Lyme Disease). Pediatr Rev 2014; 35: 500–9.  
34.  Steere AC, Bartenhagen NH, Craft JE, Hutchinson GJ, Newman JH, Rahn DW, et al. The 
early clinical manifestations of Lyme disease. Ann Intern Med 1983; 99: 76–82.  
35.  Rupprecht TA, Koedel U, Fingerle V, Pfister H-W. The Pathogenesis of Lyme 
Neuroborreliosis: From Infection to Inflammation. Mol Med 2008; 14: 205–12.  
36.  Wormser GP, Liveris D, Nowakowski J, Nadelman RB, Cavaliere LF, McKenna D, et al. 
Association of specific subtypes of Borrelia burgdorferi with hematogenous 
dissemination in early Lyme disease. J Infect Dis 1999; 180: 720–5.  
37.  Grygorczuk S, Osada J, Świerzbińska R, Zajkowska J, Kondrusik M, Pancewicz S, et al. 
Expression of Fas receptor on human T lymphocytes under stimulation with Borrelia 
burgdorferi sensu lato – preliminary results. Advances in Medical Sciences 2010; 55: 
228–34.  
38.  Grygorczuk S, Świerzbińska R, Moniuszko A, Kondrusik M, Zajkowska J, Czupryna P, et 
al. Synthesis of Th17 cytokines in the culture of peripheral blood mononuclear cells 
stimulated with Borrelia burgdorferi sensu lato. Annals of Agricultural and 
Environmental Medicine 2016; 23: 242–7.  
61 
 
39.  Strle K, Drouin EE, Shen S, El Khoury J, McHugh G, Ruzic-Sabljic E, et al. Borrelia 
burgdorferi Stimulates Macrophages to Secrete Higher Levels of Cytokines and 
Chemokines than Borrelia afzelii or Borrelia garinii. J Infect Dis 2009; 200: 1936–43.  
40.  Stinco G, Ruscio M, Bergamo S, Trotter D, Patrone P. Clinical Features of 705 Borrelia 
burgdorferi Seropositive Patients in an Endemic Area of Northern Italy. 
ScientificWorldJournal 2014; 2014. Available from: http://www.ncbi.nlm.nih.gov/ 
pmc/articles/PMC3914583/ 
41.  Logar M, Ruzić-Sabljić E, Maraspin V, Lotric-Furlan S, Cimperman J, Jurca T, et al. 
Comparison of erythema migrans caused by Borrelia afzelii and Borrelia garinii. 
Infection 2004; 32: 15–9.  
42.  Carlsson S-A, Granlund H, Jansson C, Nyman D, Wahlberg P. Characteristics of 
erythema migrans in Borrelia afzelii and Borrelia garinii infections. Scand J Infect Dis 
2003; 35: 31–3.  
43.  Strle F, Nadelman RB, Cimperman J, Nowakowski J, Picken RN, Schwartz I, et al. 
Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi 
sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med 
1999; 130: 32–6.  
44.  Wormser GP, Masters E, Nowakowski J, McKenna D, Holmgren D, Ma K, et al. 
Prospective clinical evaluation of patients from Missouri and New York with erythema 
migrans-like skin lesions. Clin Infect Dis 2005; 41: 958–65.  
45.  Sood SK. Lyme disease in children. Infect Dis Clin North Am 2015; 29: 281–94.  
46.  Arnež M, Ružić-Sabljić E. Borrelial Lymphocytoma in Children. Pediatr Infect Dis J 2015; 
34: 1319–22.  
47.  Wormser GP. Hematogenous dissemination in early Lyme disease. Wien Klin 
Wochenschr 2006; 118: 634–7.  
48.  Esposito S, Bosis S, Sabatini C, Tagliaferri L, Principi N. Borrelia burgdorferi infection 
and Lyme disease in children. Int J Infect Dis 2013; 17: e153-8.  
49.  Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme Disease in Children in 
Southeastern Connecticut. New England Journal of Medicine 1996; 335: 1270–4.  
50.  Costello JM, Alexander ME, Greco KM, Perez-Atayde AR, Laussen PC. Lyme carditis in 
children: presentation, predictive factors, and clinical course. Pediatrics 2009; 123: 
e835-41.  
51.  Maraspin V, Mrvič T, Ružić-Sabljić E, Jurčić V, Strle F. Acrodermatitis chronica 
atrophicans in children: Report on two cases and review of the literature. Ticks and 
Tick-borne Diseases 2019; 10: 180–5.  
62 
 
52.  Strle F, Ruzić-Sabljić E, Cimperman J, Lotric-Furlan S, Maraspin V. Comparison of 
findings for patients with Borrelia garinii and Borrelia afzelii isolated from 
cerebrospinal fluid. Clin Infect Dis 2006; 43: 704–10.  
53.  Ogrinc K, Lotrič-Furlan S, Maraspin V, Lusa L, Cerar T, Ružič-Sabljič E, et al. Suspected 
early Lyme neuroborreliosis in patients with erythema migrans. Clin Infect Dis 2013; 
57: 501–9.  
54.  Arnez M, Ruzić-Sabljić E. Lyme borreliosis and acute peripheral facial palsy in 
Slovenian children. Pediatr Infect Dis J 2010; 29: 182–4.  
55.  Arnez M, Pleterski-Rigler D, Luznik-Bufon T, Ruzić-Sabljić E, Strle F. Children with 
multiple erythema migrans: are there any pre-treatment symptoms and/or signs 
suggestive for central nervous system involvement? Wien Klin Wochenschr 2002; 114: 
524–9.  
56.  Steere AC. Lyme disease. N Engl J Med 2001; 345: 115–25.  
57.  Belman AL, Iyer M, Coyle PK, Dattwyler R. Neurologic manifestations in children with 
North American Lyme disease. Neurology 1993; 43: 2609–14.  
58.  Millner MM, Müllegger RR, Spork KD, Stanek G. Lyme borreliosis of central nervous 
system (CNS) in children: a diagnostic challenge. Infection 1991; 19: 273–8.  
59.  Peltomaa M, Saxen H, Seppälä I, Viljanen M, Pyykkö I. Paediatric Facial Paralysis 
caused by Lyme borreliosis: A Prospective and Retrospective Analysis. Scandinavian 
Journal of Infectious Diseases 1998; 30: 269–75.  
60.  Kan L, Sood SK, Maytal J. Pseudotumor cerebri in Lyme disease: a case report and 
literature review. Pediatr Neurol 1998; 18: 439–41.  
61.  Müller D, Neubauer BA, Waltz S, Stephani U. Neuroborreliosis and isolated trochlear 
palsy. Eur J Paediatr Neurol 1998; 2: 275–6.  
62.  Huisman TA, Wohlrab G, Nadal D, Boltshauser E, Martin E. Unusual presentations of 
neuroborreliosis (Lyme disease) in childhood. J Comput Assist Tomogr 1999; 23: 39–
42.  
63.  Vukelic D, Bozinovic D, Morovic M, Tesovic G, Ruzic Sabljic E, Barisic N, et al. 
Opsoclonus-myoclonus syndrome in a child with neuroborreliosis. J Infect 2000; 40: 
189–91.  
64.  Wilke M, Eiffert H, Christen H-J, Hanefeld F. Primarily chronic and cerebrovascular 
course of Lyme neuroborreliosis: case reports and literature review. Archives of 
Disease in Childhood 2000; 83: 67–71.  
65.  Rothermel H, Hedges TR, Steere AC. Optic neuropathy in children with Lyme disease. 
Pediatrics 2001; 108: 477–81.  
63 
 
66.  Arav-Boger R, Crawford T, Steere AC, Halsey NA. Cerebellar ataxia as the presenting 
manifestation of Lyme disease. Pediatr Infect Dis J 2002; 21: 353–6.  
67.  Mahne J, Kranjc BS, Strle F, Ružić-Sabljić E, Arnež M. Panuveitis caused by Borrelia 
burgdorferi sensu lato infection. Pediatr Infect Dis J 2015; 34: 102–4.  
68.  Allen NM, Jungbluth H. Lyme Neuroborreliosis: A Potentially Preventable Cause of 
Stroke. The Journal of Pediatrics 2016; 170: 334.e1.  
69.  Baumann M, Birnbacher R, Koch J, Strobl R, Rostásy K. Uncommon manifestations of 
neuroborreliosis in children. Eur J Paediatr Neurol 2010; 14: 274–7.  
70.  Binalsheikh IM, Griesemer D, Wang S, Alvarez-Altalef R. Lyme neuroborreliosis 
presenting as Alice in Wonderland syndrome. Pediatr Neurol 2012; 46: 185–6.  
71.  Correll MH, Datta N, Arvidsson HSS, Melsom HA, Thielberg AK, Bjerager M, et al. Lyme 
neuroborreliosis: a treatable cause of acute ocular motor disturbances in children. 
British Journal of Ophthalmology 2015; 99: 1401–4.  
72.  Dayan NE, Rubin LG, Di John D, Sood SK. Hypoglycorrhachia in Lyme meningitis. 
Pediatr Infect Dis J 2004; 23: 370–1.  
73.  Drenckhahn A, Spors B, Knierim E. Acute isolated partial oculomotor nerve palsy due 
to Lyme neuroborreliosis in a 5 year old girl. European Journal of Paediatric Neurology 
2016; 20: 977–9.  
74.  Ewers EC, Dennison DH, Stagliano DR. A unique case of adolescent neuroborreliosis 
presenting with multiple cranial neuritis and cochlear inflammation on magnetic 
resonance imaging. Pediatr Neurol 2015; 52: 107–9.  
75.  Francisco T, Marques M, Vieira JP, Brito MJ. Bilateral facial palsy: a form of 
neuroborreliosis presentation in paediatric age. BMJ Case Rep 2013. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603661/ 
76.  Khan S, Singh N, Dow A, Ramirez-Zamora A. Pediatric Acute Longitudinal Extensive 
Transverse Myelitis Secondary to Neuroborreliosis. Case Reports in Neurology 2015; 7: 
162–6.  
77.  Kohns M, Karenfort M, Schaper J, Laws H-J, Mayatepek E, Distelmaier F. Transient 
ischaemic attack in a 5-year-old girl due to focal vasculitis in neuroborreliosis. 
Cerebrovasc Dis 2013; 35: 184–5.  
78.  Kortela E, Hytönen J, Numminen J, Overmyer M, Saxen H, Oksi J. Cerebral vasculitis 
and intracranial multiple aneurysms in a child with Lyme neuroborreliosis. JMM Case 
Rep 2017; 4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ 
PMC5630958/ 
79.  Kurian M, Pereira VM, Vargas MI, Fluss J. Stroke-like Phenomena Revealing Multifocal 
Cerebral Vasculitis in Pediatric Lyme Neuroborreliosis. Journal of Child Neurology 
2015; 30: 1226–9.  
64 
 
80.  Lebas A, Toulgoat F, Saliou G, Husson B, Tardieu M. Stroke Due to Lyme 
Neuroborreliosis: Changes in Vessel Wall Contrast Enhancement. Journal of 
Neuroimaging 2012; 22: 210–2.  
81.  Moses JM, Riseberg RS, Mansbach JM. Lyme disease presenting with persistent 
headache. Pediatrics 2003; 112: e477-9.  
82.  Peltomaa M, Pyykkö I, Seppälä I, Viljanen M. Lyme borreliosis--an unusual cause of 
vertigo. Auris Nasus Larynx 1998; 25: 233–42.  
83.  Piché-Renaud P-P, Branson H, Yeh EA, Morris SK. Lyme disease presenting with 
multiple cranial neuropathies on MRI. IDCases 2018; 12: 117–8.  
84.  Rocha R, Lisboa L, Neves J, García López M, Santos E, Ribeiro A. Neuroborreliosis 
presenting as acute disseminated encephalomyelitis. Pediatr Emerg Care 2012; 28: 
1374–6.  
85.  Mygland A, Ljøstad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I, et al. EFNS 
guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur 
J Neurol 2010; 17: 8–16, e1-4.  
86.  Stanek G, Fingerle V, Hunfeld K-P, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: 
Clinical case definitions for diagnosis and management in Europe. Clinical 
Microbiology and Infection 2011; 17: 69–79.  
87.  Stanek G, Strle F. Lyme borreliosis: a European perspective on diagnosis and clinical 
management. Curr Opin Infect Dis 2009; 22: 450–4.  
88.  Arnez M, Luznik-Bufon T, Avsic-Zupanc T, Ruzic-Sabljic E, Petrovec M, Lotric-Furlan S, 
et al. Causes of febrile illnesses after a tick bite in Slovenian children. Pediatr Infect Dis 
J 2003; 22: 1078–83.  
89.  Arnez M, Pleterski-Rigler D, Ahcan J, Ruzić-Sabljić E, Strle F. Demographic features, 
clinical characteristics and laboratory findings in children with multiple erythema 
migrans in Slovenia. Wien Klin Wochenschr 2001; 113: 98–101.  
90.  Arnez M, Ruzić-Sabljić E, Ahcan J, Radsel-Medvescek A, Pleterski-Rigler D, Strle F. 
Isolation of Borrelia burgdorferi sensu lato from blood of children with solitary 
erythema migrans. Pediatr Infect Dis J 2001; 20: 251–5.  
91.  Arnez M, Radsel-Medvescek A, Pleterski-Rigler D, Ruzić-Sabljić E, Strle F. Comparison 
of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with 
solitary erythema migrans. Wien Klin Wochenschr 1999; 111: 916–22.  
92.  Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and 
evaluation programs. Journal of the Neurological Sciences 2001; 184: 101–22.  
93.  Cerar T, Ruzic-Sabljic E, Cimperman J, Strle F. Comparison of immunofluorescence 
assay (IFA) and LIAISON in patients with different clinical manifestations of Lyme 
borreliosis. Wien Klin Wochenschr 2006; 118: 686–90.  
65 
 
94.  Ružić-Sabljić E, Maraspin V, Stupica D, Rojko T, Bogovič P, Strle F, et al. Comparison of 
MKP and BSK-H media for the cultivation and isolation of Borrelia burgdorferi sensu 
lato. PLoS One 2017; 12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ 
PMC5295711/ 
95.  Postic D, Assous MV, Grimont PA, Baranton G. Diversity of Borrelia burgdorferi sensu 
lato evidenced by restriction fragment length polymorphism of rrf (5S)-rrl (23S) 
intergenic spacer amplicons. Int J Syst Bacteriol 1994; 44: 743–52.  
96.  Portnoï D, Sertour N, Ferquel E, Garnier M, Baranton G, Postic D. A single-run, real-
time PCR for detection and identification of Borrelia burgdorferi sensu lato species, 
based on the hbb gene sequence. FEMS Microbiol Lett 2006; 259: 35–40.  
97.  Li D-C, Liu C-W, Hu SC. A learning method for the class imbalance problem with 
medical data sets. Computers in Biology and Medicine 2010; 40: 509–18.  
98.  Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: Synthetic Minority Over-
sampling Technique. JAIR 2002; 16: 321–57.  
99.  Hastie T, Tibshirani R, Friedman F. The elements of statistical learning. Data mining, 
inference, and prediction. California, Stanford: Springer 2008; 764p.  
100.  Leskovec A. Pogostnost lymskega meningitisa pri otrocih s sindromom seroznega 
meningitisa (master’s thesis, COBISS.SI-ID: 24089049). Ljubljana: Faculty of Medicine, 
University of Ljubljana; 2008. 51 p. 
101.  Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of Lyme 
Borreliosis. Clin Microbiol Rev 2005; 18: 484–509.  
102.  Wilske B, Fingerle V, Schulte-Spechtel U. Microbiological and serological diagnosis of 
Lyme borreliosis. FEMS Immunology & Medical Microbiology 2007; 49: 13–21.  
103.  Ružić-Sabljić E, Cerar T. Progress in the molecular diagnosis of Lyme disease. Expert 
Review of Molecular Diagnostics 2017; 17: 19–30.  
104.  Cerar T, Ogrinc K, Cimperman J, Lotrič-Furlan S, Strle F, Ružić-Sabljić E. Validation of 
Cultivation and PCR Methods for Diagnosis of Lyme Neuroborreliosis. J Clin Microbiol 
2008; 46: 3375–9.  
105.  Arnež M, Ružić-Sabljić E. Borrelia burgdorferi sensu lato bacteremia in Slovenian 
children with solitary and multiple erythema migrans. Pediatr Infect Dis J 2011; 30: 
988–90.  
106.  Tuerlinckx D, Bodart E, Jamart J, Glupczynski Y. Prediction of Lyme meningitis based on 
a logistic regression model using clinical and cerebrospinal fluid analysis: a European 
study. Pediatr Infect Dis J 2009; 28: 394–7.  
107.  Broekhuijsen-van Henten DM, Braun KPJ, Wolfs TFW. Clinical presentation of 
childhood neuroborreliosis; neurological examination may be normal. Arch Dis Child 
2010; 95: 910–4.  
66 
 
108.  Södermark L, Sigurdsson V, Näs W, Wall P, Trollfors B. Neuroborreliosis in Swedish 
Children: A Population-based Study on Incidence and Clinical Characteristics. The 
Pediatric Infectious Disease Journal 2017; 36: 1052–6.  
109.  Cohn KA, Thompson AD, Shah SS, Hines EM, Lyons TW, Welsh EJ, et al. Validation of a 
clinical prediction rule to distinguish Lyme meningitis from aseptic meningitis. 
Pediatrics 2012; 129: e46-53.  
110.  Skogman BH, Croner S, Nordwall M, Eknefelt M, Ernerudh J, Forsberg P. Lyme 
neuroborreliosis in children: a prospective study of clinical features, prognosis, and 
outcome. Pediatr Infect Dis J 2008; 27: 1089–94.  
111.  Skogman BH, Glimåker K, Nordwall M, Vrethem M, Ödkvist L, Forsberg P. Long-term 
clinical outcome after Lyme neuroborreliosis in childhood. Pediatrics 2012; 130: 262–
9.  
112.  Christen HJ, Hanefeld F, Eiffert H, Thomssen R. Epidemiology and clinical 
manifestations of Lyme borreliosis in childhood. A prospective multicentre study with 
special regard to neuroborreliosis. Acta Paediatr Suppl 1993; 386: 1–75.  
113.  Bingham PM, Galetta SL, Athreya B, Sladky J. Neurologic manifestations in children 
with Lyme disease. Pediatrics 1995; 96: 1053–6.  
114.  Shah SS, Zaoutis TE, Turnquist J, Hodinka RL, Coffin SE. Early differentiation of Lyme 
from enteroviral meningitis. Pediatr Infect Dis J 2005; 24: 542–5.  
115.  Cook SP, Macartney KK, Rose CD, Hunt PG, Eppes SC, Reilly JS. Lyme disease and 
seventh nerve paralysis in children. Am J Otolaryngol 1997; 18: 320–3.  
116.  Øymar K, Tveitnes D. Clinical characteristics of childhood Lyme neuroborreliosis in an 
endemic area of northern Europe. Scandinavian Journal of Infectious Diseases 2009; 
41: 88–94.  
117.  Avery RA, Frank G, Glutting JJ, Eppes SC. Prediction of Lyme meningitis in children 
from a Lyme disease-endemic region: a logistic-regression model using history, 
physical, and laboratory findings. Pediatrics 2006; 117: e1-7.  
118.  Garro AC, Rutman M, Simonsen K, Jaeger JL, Chapin K, Lockhart G. Prospective 
validation of a clinical prediction model for Lyme meningitis in children. Pediatrics 
2009; 123: e829-34.  
119.  Cerar T, Ogrinc K, Strle F, Ružić-Sabljić E. Humoral Immune Responses in Patients with 
Lyme Neuroborreliosis. Clin Vaccine Immunol 2010; 17: 645–50.  
120.  Stanek G, Lusa L, Ogrinc K, Markowicz M, Strle F. Intrathecally produced IgG and IgM 
antibodies to recombinant VlsE, VlsE peptide, recombinant OspC and whole cell 
extracts in the diagnosis of Lyme neuroborreliosis. Med Microbiol Immunol 2014; 203: 
125–32.  
67 
 
121.  Karlsson M, Hovind-Hougen K, Svenungsson B, Stiernstedt G. Cultivation and 
characterization of spirochetes from cerebrospinal fluid of patients with Lyme 
borreliosis. J Clin Microbiol 1990; 28: 473–9.  
 
